Molecular Docking and Synthesis of 1, 2, 4 - Triazin Analogue of Diclofenac as Potential Ligand for Chlorpromazine Induced Parkinson’s in Rat Model by Sudhakar, P
  
MOLECULAR DOCKING AND SYNTHESIS OF 1, 2, 4 - TRIAZIN 
ANALOGUE OF DICLOFENAC AS POTENTIAL LIGAND FOR 
CHLORPROMAZINE INDUCED PARKINSON’S IN RAT MODEL 
 
A Dissertation submitted to 
THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY 
Chennai-600032 
 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN 
PHARMACOLOGY 
 
Submitted by 
S. POORANA PUSHKALAI 
REG. NO.: 261525552 
 
Under the Guidance of 
Mr. P. SUDHAKAR, M. Pharm.,  
Assistant Professor, Department of Pharmacology  
 
 
 
 
DEPARTMENT OF PHARMACOLOGY 
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY, ELAYAMPALAYAM, 
TIRUCHENGODE-637205, NAMAKKAL DISTRICT, TAMIL NADU. 
 
OCTOBER-2017 
 
  
                    SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
Elayampalayam, Tiruchengode- 637205 
                     Namakkal (DT.), Tamilnadu. 
            Phone: 04288-234417  
                                     Fax: 04288-234417     
 
Dr. G. MURUGANANTHAN, M. Pharm., Ph.D., 
PRINCIPAL 
 
CERTIFICATE 
This is to certify that the Dissertation entitled “Molecular Docking and 
Synthesis of 1, 2, 4 – Triazin Analogue of Diclofenac as Potential Ligand for 
Chlorpromazine Induced Parkinson’s in Rat Model” submitted to The Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, is a bonafide project work of                                       
S. POORANA PUSHKALAI (Reg. No: 261525552) carried out in the Department of 
Pharmacology, Swamy Vivekananda College of Pharmacy, Tiruchengode for the 
partial fulfillment for the degree of Master of Pharmacy under the guidance and direct 
supervision of Mr. P. SUDHAKAR, M. Pharm., in the Department of Pharmacology 
during the academic year of 2016-2017. 
 
 
Date:  
Place:                Dr. G. MURUGANANTHAN, M. Pharm., Ph.D., 
 
 
  
  SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
                                Elayampalayam, Tiruchengode- 637205 
                                  Namakkal (DT.), Tamilnadu. 
                                  Phone: 04288-2344 
                                  Fax: 04288-234417     
 
Dr. V. VINOTH PRABHU, M. Pharm., Ph.D.,  
 
Head, Department of Pharmacology 
 
 
CERTIFICATE 
This is to certify that the Dissertation entitled “Molecular Docking and 
Synthesis of 1, 2, 4 – Triazin Analogue of Diclofenac as Potential Ligand for 
Chlorpromazine Induced Parkinson’s in Rat Model” submitted to The Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, is a bonafide project work of          
S. POORANA PUSHKALAI (Reg. No: 261525552) carried out in the Department of 
Pharmacology, Swamy Vivekananda College of Pharmacy, Tiruchengode for the 
partial fulfillment for the degree of Master of Pharmacy under the direct guidance and 
supervision of Mr. P. SUDHAKAR, M. Pharm., in the Department of Pharmacology 
during the academic year of 2016-2017. 
 
 
 
Date:  
 
Place:                                                     Dr. V. Vinoth Prabhu, M. Pharm, Ph. D., 
 
 
 
 
 
  
   SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
                                      Elayampalayam, Tiruchengode- 637205 
                 Namakkal (DT.), Tamilnadu. 
       Phone: 04288-234417  
                                      Fax: 04288-234417     
 
Mr. P.SUDHAKAR, M. Pharm., 
Assistant Professor, Department of Pharmacology 
 
 
CERTIFICATE 
This is to certify that the Dissertation entitled “Molecular Docking and 
Synthesis of 1, 2, 4 – Triazin Analogue of Diclofenac as Potential Ligand for 
Chlorpromazine Induced Parkinson’s in Rat Model” submitted to The Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, is a bonafide project work of          
S. POORANA PUSHKALAI (Reg. No.: 261525552) carried out in the Department of 
Pharmacology, Swamy Vivekananda College of Pharmacy, Tiruchengode, for the 
partial fulfillment for the degree of Master of Pharmacy under my direct guidance and 
supervision during the academic year of 2016-2017. 
This work is original and has not been submitted earlier for the award of any 
other Degree or Diploma of this or any other university  
Date:  
Place:                                                                    Mr. P.SUDHAKAR, M. Pharm., 
 
 
 
 
 
 
 
  
DECLARATION 
 
 
This is to certify that the Dissertation entitled “Molecular Docking and 
Synthesis of 1, 2, 4 – Triazin Analogue of Diclofenac as Potential Ligand for 
Chlorpromazine Induced Parkinson’s in Rat Model” submitted to The Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, is a bonafide project work carried 
out myself S. POORANA PUSHKALAI (Reg. No: 261525552) in the Department of 
Pharmacology, Swamy Vivekananda College of Pharmacy, Tiruchengode for the 
partial fulfillment for the degree of Master of Pharmacy under the guidance and direct 
supervision of Mr. P. SUDHAKAR, M. Pharm., in the Department of Pharmacology 
during the academic year of 2016-2017. 
Hereby I declare that this work embedded in the thesis is original and not 
submitted in part or full for any other degree of this or any other university. 
 
S. POORANA PUSHKALAI          
                                      (REG. NO: 261525552) 
 
        
 
         
 
 
    
  
 
EVALUATION CERTIFICATE 
 
 This is to certify that the Dissertation entitled “Molecular Docking and 
Synthesis of 1, 2, 4 – Triazin Analogue of Diclofenac as Potential Ligand for 
Chlorpromazine Induced Parkinson’s in Rat Model” submitted to The Tamil 
Nadu Dr. M.G.R. Medical University, Chennai, in partial fulfillment for the degree of 
Master of Pharmacy. This was carried out by                                         S. POORANA 
PUSHKALAI (Reg. No: 261525552) under the guidance and direct supervision of 
Mr. P. SUDHAKAR, M. Pharm., in the Department of Pharmacology, Swamy 
Vivekananda College of Pharmacy, Tiruchengode for the during the academic year 
of 2016-2017. 
 
 
Internal Examiner                                                                    External Examiner                                                                          
 
 
 
Examination centre: Swamy Vivekanandha College of Pharmacy,                      
                                    Elayampalayam, Tiruchengode. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT                                                       
  
ACKNOWLEDGEMENT 
First and foremost, I bow down before LORD ALMIGHTY, the most humane, 
the most indulgent. All praise and thanks are due to him who had bestowed us with 
health and courage during the course of my work and throughout my life till this 
every second. 
I feel it a great honour to express my deep sense of gratitude and indebtedness 
to my wonderful project guide Mr. P. SUDHAKAR.P, M. Pharm., Assistant Professor, 
Department of Pharmacology, for his invigorate guidance, felicitous advice, 
constructive help, suggestions, encouragement and friendly support during the whole 
course of my work, punctilious and valuable hints with energizing criticism during the 
course of dissertation work. Indeed without her guidance and optimistic approach 
this project wouldn’t have been a successful one. 
It is difficult to overstate my gratitude to Dr. G. MURUGANANTHAN, M. 
Pharm., Ph.D., and Principal of this institution. His enthusiasm and integral view on 
research and his mission for providing ‘only high-quality work and not less’, has 
made a deep impression on me. I owe him lots of gratitude for having me shown this 
way of research. 
I feel it a great to express my deep sense of gratitude and indebtedness to my 
Head of Department of Pharmacology of this institution Dr. V. VINOTH PRABHU, 
M.Pharm., Ph.D., thanking for his support encouragement and his constructive ideas 
at each and every stage of the project which were the driving forces for me to 
complete this thesis.  
 
 
  
I submit my sincere and respectful regards to our beloved chairman and 
secretary Vidyaratna, Rashtriya rattan, Hind rattan,                                                      
Prof. Dr. M. KARUNANITHI, B.Pharm, M.S., Ph.D. D. Litt, who provided all the 
facilities in this institution enabling us to do a work of this magnitude. 
I also extend my sincere equal thanks to Mr. R. ANAND, M.Pharm,                          
Ms. S. PRIYADHARSHINI, M.Pharm, and Ms. K.B. SUCHITHRA, B.Pharm, 
Department of Pharmacology for their valuable advice and friendly support 
throughout the course of study. 
I remain my sincere thanks to non-teaching staff Mr. V. KARUNAKARAN,        
Mrs. L. SATHIYA, and Ms. S. GOWRI, Department of pharmacology, SVCP Animal 
house care taker Mr. S. MARI and Library staff Mrs. K. SHARMILA,                       
Mr. P. SAHAYARAJU for help to finish the project work in a successful manner. 
I am immensely grateful to staff of all other departments, and all nonteaching 
staffs, Swamy Vivekanandha college of Pharmacy, Tiruchengode, for their garnered 
blessings showered on me throughout my academic career. 
I owe my heartfelt gratitude to my respected Family members, I take this 
privilege and pleasure to acknowledge my hero Mr. K. SARAVANAN, B.E, my 
heroine Mrs. S. PREMA, my princess Ms. S. VAISHNAVI, my king                    Mr. 
N. KRISHNAN and my Queen Mrs. K. BABY Late whose unconditional love, 
support and encouragement shaped up my life. Without their moral support, I am 
nothing and I dedicate all my achievements at their feet. 
FRIENDS are treasures to me and it is very difficult to overstate my thanks to 
M. SUGANESWARI, KM. PREETU SHUKLA, S. HARIPRIYA and all my friends. It 
has been my happiest time to study, discuss, laugh and play with them all. I express 
my whole hearted thanks to my friends. 
  
 I would like to thanks THE TAMIL NADU DR. M. G. R. MEDICAL 
UNIVERSITY for providing a nice environment for learning. 
My sincere gratitude and appreciation goes to all who have directly or 
indirectly contributed to my project successfully. 
 
S. POORANA PUSHKALAI 
(REG. NO: 261525552) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
ABSTRACT 
  
ABSTRACT 
Title                        :   Molecular Docking and Synthesis of       1, 2, 
4–Triazin Analogue of Diclofenac as 
Potential Ligand for Chlorpromazine 
Induced Parkinson’s in Rat Model. 
 
Name            :   S. POORANA PUSHKALAI  
  
Register Number           :    261525552 
 
Degree to which submitted       :   Master of Pharmacy in Pharmacology 
 
Guide                                        :   Mr. P. Sudhakar, M. Pharm., 
  
Department                               :   Department of pharmacology  
 
      College                               :   Swamy Vivekanandha College of Pharmacy, 
Tiruchengode. 
 
      University                        :  Tamil Nadu Dr. M.G.R Medical University, 
Chennai- 32. 
 
      Year                                          :   2016-2017 
 
Aim: 
 Parkinson’s disease (PD) is a common neurodegenerative disorder, which is 
characterized by slowly progressive loss of dopaminergic neurons associated with 
substantial. The present study was aimed for molecular docking and synthesis of 1, 
2, 4–Triazin analogue of diclofenac as potential ligand for chlorpromazine induced 
Parkinson’s in rat model. 
 
 
 
  
Materials and methods: 
 Twenty four Albino Wistar male Rats weighing 250-270 gm were randomly 
assigned to four groups, each group contain 6 animals. Group I Vehicle group-
Received 1% Gum acacia + distilled water p.o for 14 days, Group II Negative control 
group- Received Chlorpromazine 3mg/kg, i.p. (dissolved with 1% gum acacia in 
distilled water suspension), Group III Standard group - Received Chlorpromazine 
(3mg/kg/day), i.p. + Diclofenac (10mg/kg/day) p. o., Group IV treatment group- 
Received Chlorpromazine (3mg/kg/day) i.p. + 1,2,4-Triazin derivative of Diclofenac 
at dose of 30mg/kg, p. o. Parkinson’s disease (PD) was induced by intra peritoneal 
injection of chlorpromazine 3mg/kg, i. p (dissolved with 1% gum acacia in distilled 
water suspension) daily for a period of 14 days. The 1, 2, 4-Trianine analogue of 
diclofenac was synthesised and evaluated against chlorpromazine induced PD by 
monitoring in vivo behavioural paramerters like muscle coordination, cognitive 
performance, catalepsy activity, Biochemical estimation of SGPT, SGOT, ALP, Total 
bilirubin, urea, creatinie and brain antioxidant levels, Acetylcholine, dopamine. 
Changes were confirmed by Histopathological studies.   
 
Results:  
 Molecular docking of 1, 2, 4- Triazin derivative of diclofenac, binding scores of 
designed ligand was 1-10 scores with D3 protein, DDC, AA2AR, MAPK and MAO-B 
enzymes ranging from -6.35 to -5.64 Kcal/mol, -6.86 to -5.81 Kcal/mol, -6.11 to -
5.02, -8.67 to -4.63 Kcal/mol, and -10.25 to -6.76 Kcal/mol respectively. Treatment 
group shows significant increase the body weight, feed intake, Locomotion action, 
muscle coordination, cognitive performance and dopamine level, also decrease in 
muscle rigidity, oxidative stress and cholinergic over activity. 
Conclusion:  
1, 2, 4 -Triazin derivative of diclofenac shows significantly anti Parkinson’s 
activity against chlorpromazine induced PD rats with milder GI toxicity as compared 
to the diclofenac treatment. Further clinical data are required to explore this 
Analogue of diclofenac as Potential Ligand for improving the status of PD patients. 
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CHAPTER - 1 
INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative brain disorder. 
It is characterized by diminished facial expression, stooped posture, slowness of 
voluntary movement, festinating gait (progressively short- ended, accelerated steps), 
rigidity, and a “pill- rolling|” tremor but also of many other central and peripheral 
neuronal systems1. More than 1 million people in the United States are affected by 
the disease. It usually begins after 50 years of age; most cases are diagnosed in the 
sixth and seventh decade of life. PD, the most common from Parkinsonism, is 
named after James Parkinson, a British physician who first described the disease in 
1817 on the “shaking palsy” 2. 
The aetiology of PD is unknown but several mechanisms have been proposed 
including environmental toxins, oxidative stress and neuro inflammation. The 
involvement of such dopamine and non-dopaminergic systems is responsible for the 
occurrence of the motor and non-motor Parkinson’s symptoms. Non-motor 
symptoms and their management are now recognized as an important unmet need 
in PD. They affect the great majority of PD patients and may sometimes be more 
closely related to reduce quality of life than the core motor symptoms 3. 
A pathological classification of Lewy body diseases includes the loss of 
pigmented dopaminergic neurons and the presence of Lewy bodies. Progressive 
degeneration of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc), which project to the striatum (the nigrostriatal pathway), results in the loss of 
dopaminergic functions in individuals with PD. PD is characterized by the 
accumulation of intracellular protein aggregates, Lewy bodies and Lewy neuritis 
which composed of primarily protein α-synuclein. These neurons contain the 
neurotransmitter DA, and their projecting nerve fibers reside in the striatum 4, 5. 
 In Dopamine loss in the basal ganglia triggers prominent secondary 
morphological changes and its depletion also triggers changes in the density and 
sensitivity of dopamine receptors 6. DA are two types of D1 (excitatory type) and D2 
(inhibitor type), influence motor activity in the extra pyramidal system. Components 
of this system include the basal ganglia, which involves the internal globus pallidal 
  
segment (GPi) of the ventral striatum, and the pars reticulata portion of the 
substantia nigra (SNpr). The loss of dopamine in the striatum of PD patients results 
in increased activity in the GPi/SNpr circuits and subsequent gamma aminobutyric 
acid (GABA) dysfunction, leading to inhibition of the thalamus 7, 8. 
Non steroidal anti-inflammatory drugs (NSAIDs) are among the most 
frequently prescribed drugs in modern medicine. NSAID use is however associated 
with several serious side effects, with considerable associated morbidity and 
mortality 9. The best-known mechanism of action of NSAIDs is associated with 
inhibition of prostaglandin (PG) and thromboxane (TX) production by interaction with 
cyclooxygenase (COX-1 and COX-2) enzymes. It is now known that there are two 
structurally distinct forms of the cyclo-oxygenase enzyme (COX-1 and COX-2). 
COX-1 is a constitutive member of normal cells and COX-2 is induced in 
inflammatory cells. Inhibition of COX-2 activity represents the most likely mechanism 
of action for NSAID-mediated analgesia, while the ratio of inhibition of COX-1 to 
COX-2 by NSAIDs should determine the likelihood of adverse effects 10. 
NSAIDs and neurological diseases is an important mechanism in defence 
responses to progression of neurodegenerative diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), and other neurological disorders. The over-
expression of COX-1 and COX-2 has been found in the central nervous system of 
patients with ischemic, traumatic brain injury and those with neurodegenerative 
diseases such as AD and PD, which indicates that COX mediated 
neuroinflammation, is a critical component in neuronal degeneration. As reactive 
microglia were first observed in the vicinity of degenerating dopaminergic substantia 
nigral regions of post-mortem brains taken from patients with Parkinson’s disease. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron 
degeneration in animal models of PD 11. 
Non steroidal anti-inflammatory drugs (NSAIDs) readily cross blood brain 
barriers and inhibits microgial released cyclo-oxygenases and other cytokines. 
Investigated that diclofenac along with sertraline signification inhibit inflammatory 
cytokines like TNF-α, interleukins and promote the release of IL -10 which is an anti-
inflammatory in nature. In addition, different animal experimental studies have shown 
that COX-2 inhibitors are reversed in rodents with decrease in inflammatory 
  
cytokinase. Diclofenac is more potent in inhibiting COX-2 than COX-1 isoenzymes 12. 
A new anti-Parkinson’s drug diclofenac is effective in animal models and in patients 
with early stage of PD. It has a complex mechanism of action that involves 
uncompetitive, low affinity NMDA receptor open-channel blocking. Additionally, 
diclofenac exhibits anti radical and immunuotropic effects. 
1, 2, 4-Triazine derivative as antagonists of Adenosine A2 receptor is 
expressed in the basal ganglia where it functionally opposes the actions of the 
dopamine D2 receptor. i.e., inhibition of the A2 receptor leads to enhancement of D2 
receptor function 13. 
Several previous studies have suggested that diclofenac may elicit 
appreciable GI irritation, bleeding and ulceration produced. Synthetic approaches 
based upon chemical modification of diclofenac have been taken with the aim of 
improving safety profile and in turn therapeutic window. Carboxylic group is a major 
reason for the GI toxicity of diclofenac. Structural replacement of carboxyl group may 
reduce the GI toxicity. Previous study reported that 1, 2, 4-Triazin derivative may 
possess appropriate action on Parkinson’s action. Based on above, fact this study 
was aimed for replacement of carboxylic group with 2-Chloroacetamide to produce 
the 1, 2, 4 –Triazin derivative of diclofenac as potential target for PD 14. 
Nowadays, the discovery of new drugs to treat chronic diseases without 
adverse effects is one of the major challenges for pharmaceutical industry 15, 16. 
Among the strategies useful to discovering new drugs, the molecular modification is 
very promising strategy. Based on this 1, 2, 4-Triazine derivative of molecular 
docking studies was done against ligands 17. 
Hence this study was designed to do synthesis and evaluation of 1, 2, 4–
Triazin analogue of diclofenac as potential ligand to improve the dopamine level in 
the PD.  
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 CHAPTER - 2 
LITERATURE REVIEW 
2.1 NEURODEGENERATIVE DISEASE 
          Neurodegenerative diseases are commonly defined as disorders with selective 
loss of neurons and distinct involvement of functional system defining clinical 
presentation18. “Neurodegeneration” Etymologically, the word is composed of the 
prefix “neuro-,” which designates nerve cells (i.e., neurons), and “degeneration,” 
which refers to, the presence of tissues or organs, losing structure or function 19. 
          Neurodegenerative disorders (ND) are characterized by progressive 
dysfunction and loss of neurons and synapses in selected (vulnerable) areas of the 
nervous system. The major basic processes inducing ND are considered as 
multifactorial such as genetic, environmental, and endogenous factors related to 
aging 20. 
          In ND due to slow progressive loss of neurons in the central nervous system 
(CNS), affecting brain functions such as movement disorders, cognitive impairment, 
dysautonomia and memory 21. Examples for NDs include Alzheimer's disease (AD), 
Parkinson's disease (PD), Huntington's disease (HD), and multiple system atrophy 
(MSA) 22. 
2.1.1 HISTORY 
          J. F. Bray was the first author to include the adjective neurodegenerative in the 
title of a medical article. It was published in 1965 in a British journal and was 
followed in 1968 by an article of D. A. Drachman in the American journal. Bray 
described a child with abnormal hair and “spastic dementia” and Drachman reported 
four cases of progressive ophthalmoplegia and CNS disorders.  
          The authors provided no definition for the term neurodegenerative but they 
grouped the so-called neurodegenerative disorders “for convenience” under three 
headings: hereditary neuropathies, hereditary spinocerebellar degenerations, and 
motor neuron disease. Neurodegenerative diseases are predominantly genetic 
disorders 23. 
         According to Prusiner, neurodegenerative diseases are progressive nervous 
system disorders of protein processing. 25 years ago, there was little understanding 
  
of the causes of neurodegeneration. He explains, “a brief list of more common 
disorders and a few less common maladies” comprised Prion diseases, dementias, 
Parkinson disease and related disorders, motor neuron disease, Huntington disease, 
and spinocerebellar atrophies.’ 
          The Medical Research Council (MRC) states in a strategic review that 
neurodegenerative diseases are incurable and debilitating conditions that result in 
progressive deterioration or death of neuron cells. They include Parkinsonism 
diseases, Alzheimer’s disease and other dementias, Huntington disease, motor 
neurone disease, Creutzfeldt-Jacob Disease, and multiple sclerosis 23. 
         However, demographically all over the world approximately 7.5 percent belong 
to the 60+ generation billion peoples who are battling from the neurodegenerative 
problems. In India is the home of more than eighty million people older than sixty 
years as per the 2011 Census.  
          According to World Health Organization (WHO), the rate of growth will be the 
highest (around 336%) in India, followed by China, South Asia, and western Pacific 
regions, 235-393% in Latin America and Africa, and the lowest (100%) in developed 
regions. The number of persons with dementia double every five years of age and 
so. India will have one of the largest numbers of elders with this degenerative 
problem 24. 
 
2.1.2 ETIOLOGY AND PATHOLOGY 
         The etiology and pathogenesis of these devastating diseases remain largely 
unknown; however, the study of the neurochemistry and synaptic transmission. The 
different neurotransmitter change has helped to characterize involvement of specific 
subpopulations of neurons. The pattern of selective vulnerability of neurons provides 
important clues to pathogenesis and genetic regulation of neuronal development, 
and endogenous and exogenous neurotoxins 25. Neurodegenerative disorders (NDD) 
constitute a set of pathological conditions originating from slow progressive and 
irreversible dysfunction and loss of neurons and synapses in selected areas of the 
nervous system 26. Cellular and sub cellular pathology, this means whether neurons 
or glial cells (either or both astro- and oligodendroglia), including which compartment 
of the cells, show pathological protein deposits; or whether these are found 
extracellularly 27. 
  
2.1.3 CLASSIFICATION  
         A nosological classification of neurodegenerative diseases is based on clinical 
presentation, Anatomical Involvement of Neuronal Loss Underlying Clinical 
Symptomatology and Neuropathological-Biochemical Classification  
 
2.1.3.1 Anatomical Involvement of Neuronal Loss Underlying Clinical 
Symptomatology            
         Cognitive decline, dementia, and alterations in high-order brain functions are 
associated with involvement of the entorhinal cortex, hippocampus, limbic system 
and neocortical areas. A subtype of dementia is frontotemporal dementia (FTD), 
which is associated with degeneration of the frontal and temporal lobes 
(frontotemporal lobar degeneration, FTLD). 
          In movement disorders the basal ganglia, thalamus, brainstem nuclei, 
cerebellar cortex and nuclei, motor cortical areas and lower motor neurons of the 
spinal cord are involved. Combinations of these symptoms are observed in some 
diseases (i.e., prion diseases) early during the clinical course and in many disorders 
during the Progression 28. 
2.1.3.2 Neuropathological-Biochemical Classification 
          This focuses primarily on the evaluation of the anatomical distribution of 
neuronal loss, and additional histological features (e.g., vascular lesions or 
spongiform change of the neuropil), and the distinction of intracellular and 
extracellular protein accumulations, which are analyzed by immunohistochemistry 
complemented by biochemistry. There are some aspects, which need to be clarified 
to understand the neuropathological approach.   
           Firstly, not all protein-deposits visible by immunohistochemical methods show 
the amyloid staining property (means that a particular structure shows applegreen 
birefringence under polarized light when stained with the Congo red dye) even 
though they are composed of proteins with highly ordered stacks of β - sheet-rich 
elements. 
           Secondly, for some proteins, synaptic location is mentioned; however, except 
in the case of prion disease, this is not respected for diagnostic classifications. It is 
important to distinguish the subcellular location of the intracellular deposits; whether 
  
they are nuclear, cytoplasmic, or neuritic (axonal or dendrites), or in cellular 
processes (i.e., for astrocytes). For some diseases, only morphological criteria are 
used for subtyping, whereas for others biochemical modifications or even a gene 
polymorphism are also considered. For all neurodegenerative proteinpathies there 
are hereditary forms described 29. 
2.1.4 MECHANISM OF ND  
           The mechanisms that cause neurodegeneration includes; 1) genetic 
mutations, 2) protein misfolding, 3) proteinopathy, 4) neuronal cell membrane 
damage, 5) mitochondrial dysfunction, 6) axonal transport defects and 7) 
programmed cell  death or apoptosis. The based on clinical presentations and 
epidemiological studies have also incriminated age, environmental toxins and 
genetics as causation factors 30. 
2.1.5 SYMPTOMS  
         These are determined by the anatomical region showing neuronal dysfunction 
or loss and do not necessarily reflect the molecular changes in the background.  
         Accordingly, in association with a neurodegenerative syndrome one can define 
anatomical, cellular and protein vulnerability. Genetic alterations can also lead to 
these alterations or influence the susceptibility to develop these diseases. 
 
Figure No 1. Symptoms of Neurodegenerative Disorder 
2.2 PARKINSON’S DISEASES 
           Parkinson’s disease (PD) is a common, slowly progressive neurodegenerative 
disorder without a cure and affecting a wide range of motor and non-motor functions, 
and leading to marked disability in its later stages 31. It is mainly characterized by 
diminished facial expression, stooped posture, slowness of voluntary movement, 
festinating gait (progressively short- ended, accelerated steps), rigidity and a pill- 
  
rolling tremor 32. Clinically, PD is associated with resting tremor (trembling), postural 
instability, rigidity, bradykinesia (slowness and minimal movement) and an 
impairment of postural balance leading to disturbance of gait and falling 33. 
 
Figure No 2. Parkinson’s symptoms 
2.2.1 CLINICAL FEATURES 
          Motor Symptoms: From the motor standpoint PD is characterized by a clinical 
syndrome universally known as Parkinson’s, which includes four cardinal features: 
bradykinesia, rest tremor, rigidity, and postural and gait impairment. One should bear 
in mind that these are not always observed in every patient, at least in a given time 
frame. 
2.2.1.1 Bradykinesia refers to slowness of movements with a progressive loss of 
amplitude or speed during attempted rapid alternating movements of body 
segments. some repetitive movements as quickly and widely as possible, namely, 
opening and closing the hand, tapping thumb and index fingers, or tapping the foot 
on the ground. It can also be searched for globally by observing the spontaneous 
movements while sitting, standing up from a chair, or walking. Other clinical displays 
of bradykinesia are hypomimia (decreased facial expression and eye blinking, 
termed “poker face” in milder stages, hypophonia, micrographia (progressively 
smaller handwriting), and difficulty swallowing. 
2.2.1.2 Rest tremor is the most common and easily recognized symptom of PD. 
Tremors are unilateral, occur at a frequency between 4 and 6 Hz, and almost always 
are prominent in the distal part of an extremity. Hand tremors are described as 
  
supination–pronation (‘‘pill-rolling’’) tremors that spread from one hand to the other. 
Rest tremor with PD can also involve the lips, chin, jaw and legs but, unlike essential 
tremor, rarely involves the neck/head or voice. Parkinson’s related postural tremor 
(‘‘re-emergent tremor’’) is differentiated from essential tremor in that the appearance 
of tremor is often delayed after assumes an out stretched horizontal position. 
2.2.1.3 Rigidity is characterized by increased resistance, usually accompanied by 
the ‘‘cogwheel’’ phenomenon, particularly when associated with an underlying 
tremor, present throughout the range of passive movement of a limb (flexion, 
extension or rotation about a joint). It may occur proximally (eg, neck, shoulders, 
hips) and distally (eg, wrists, ankles).  
2.2.1.4 Postural and Parkinson’s gait impairment is slow, occurs on a narrow base, 
and is characterized by short shuffling steps, which gives the observer the 
impression of center of the gravity. There is decreased arm swing, turning around is 
slow and performed with multiple small steps 34. 35. 
2.2.1.5 Non motor Symptoms and the Premotor Phase of PD; PD has been 
traditionally regarded as a motor disorder, perhaps because the original account of 
the clinical features emphasized these symptoms, while failing to recognize the 
important nonmotor aspects of the disease. In addition, motor symptoms often meet 
the eye straight away, even for untrained observers. However, in recent years there 
has been an increasing interest in nonmotor symptoms of PD Because of long-term 
pathological progression, some of these non motor features may be present before 
any of the classical motor signs are noticeable, in early disease stages, such as 
hyposmia, rapid eye movement (REM) behavior disorder, constipation, and 
depression. On the other hand, features like dementia and hallucinations occur late 
in the course of disease, which is useful for distinguishing PD from other disorders 36. 
2.2.2 HISTORY  
             Parkinson’s disease was first medically described as a neurological 
syndrome by James Parkinson in 1817, though fragments of Parkinsonism can be 
found in earlier descriptions. Charcot described in full detail the arthritic changes, 
dysautonomia, and pain that can accompany Parkinson’s disease. Charcot was also 
the first to suggest the use of the term “Parkinson’s disease” rejecting the earlier 
designation of paralysis agitans or shaking palsy, because he recognized that 
Parkinson’s disease patients are not markedly weak and do not necessarily have 
  
tremor. Gowers offered one of the most memorable similes regarding Parkinsonian 
tremor. Further clinical descriptions and studies of the pathologic changes related to 
Parkinson’s disease were predominantly reported by the French neurologic school. 
Richer and Meige (1895) provided clinical and morphologic details of the progressive 
stages of Parkinsonian disability, and the former provided drawings and statues that 
remain among the most important pictorial documents related to Parkinson’s disease 
37. 
 
2.2.3 ETIOLOGY AND PATHOGENESIS 
          The view of etiological factors in PD has changed remarkably from one of a 
purely sporadic basis to the view that both environmental and genetic factors 
contribute to the onset of the illness to a point now where increasingly genetic 
predisposition must be seen as a major contributor to the underlying cause. The 
specific etiology of PD is not known 38. 
2.2.3.1 ENVIRONMENTAL FACTORS: It may increase the risk of developing PD. 
These include exposure to well water, pesticides, herbicides, and industrial 
chemicals, wood pulp mills, farming, and living in a rural environment. A number of 
exogenous toxins have been associated with the development of parkinsonism, 
including trace metals, cyanide, lacquer thinner, organic solvents, carbon monoxide, 
and carbon disulfide. There has also been interest in the possible role of 
endogenous toxins such as tetrahydroisoquinolines and beta-carbolines. However, 
no specific toxin has been found in the brain of PD patients, and in many instances 
the Parkinson’s seen in association with toxins is not that of typical Lewy body PD. 
 2.2.3.2 GENETIC FACTORS: Leads to decreasing the risk of developing PD can 
also provide valuable clues to its etiology. The evidence for cigarette smoking and 
caffeine intake in reducing risk appears clear, but there is still uncertainty over the 
role of others, for example, exercise, anti-inflammatories, anti-hypertensives (most 
notably calcium antagonists), and anti-lipidaemics 38, 39. 
2.2.3.3 ENERGY, METABOLISM, AND AGING: The excitotoxic hypothesis provides 
a link between patterns of neuronal injury, the effects of aging, and observations on 
the metabolic capacities of neurons. Since the ability of Mg2+ to block the NMDA 
receptor-channel is dependent on the membrane potential, disturbances that impair 
the metabolic capacity of neurons will tend to relieve Mg2+ blockade and predispose 
  
to excitotoxic injury. The capacity of neurons for oxidative metabolism declines 
progressively with age, perhaps in part because of a progressive accumulation of 
mutations in the mitochondrial genome. Patients with PD exhibit several defects in 
energy metabolism that are even greater than expected for their age, most notably a 
reduction in the function of complex I of the mitochondrial electron transport chain. 
Addition evidence for the role of metabolic defects in the etiology of neural 
degeneration comes from the study of patients who inadvertently self- administered 
MPTP induces studies have shown that a metabolite of MPTP induces degeneration 
of neurons similar to that observed in idiopathic PD and that its mechanism of action 
appears to be related to an ability to impair mitochondrial energy metabolism in 
dopaminergic neurons.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
2.2.3.4 OXIDATIVE STRESS: Signs of oxidative stress are abundant in the 
substantia nigra of patients with PD. Mitochondrial complex I activity is depressed. 
Levels of intrinsic antioxidants, such as glutathione, are reduced, while oxidized 
products of proteins, lipids, and DNA increase significantly. Increasing levels of 
oxidative stress can eventually lead to apoptosis through the intrinsic (or 
“mitochondrial”) PCD pathway due to cytoplasmic release of cytochrome c, which is 
proapoptotic, from dysfunctional mitochondria. 
2.2.3.5 INFLAMMATION: Local inflammation is readily apparent at sites of neuron 
loss in both PD. Most of the inflammatory cells at these sites are activated microglia, 
although lesser numbers of reactive astrocytes are seen as well. While the 
astrocytes are suspected of playing an overall protective role in PD by such 
mechanisms as sequestration and metabolization of DA, glutathione-mediated 
scavenging of ROS and production of glial-derived neurotrophic factor (GDNF), the 
microglia are believed instead to facilitate the neurodegenerative process in PD 40, 41. 
 
2.2.4 EPIDEMIOLOGY  
          PD is a prevalence of approximately 1% of the population above 60 years, 
which reaches a prevalence of nearly 4% by age 50. PD is the second most common 
neurodegenerative disorder. The mean age of PD diagnosis is in the seventh decade 
of life, but due to PD’s insidious nature, the onset of symptoms may precede clinical 
recognition by many years. The annual incidence per 100,000 inhabitants ranges 
from less than 10 to more than 20. Incidence studies may be affected by under-
  
diagnosing of PD, especially among the most elderly. This study reported an annual 
incidence of 18.8 cases per 100,000 and a mean age of onset at 70.6 years, slightly 
above the mean age of onset that we reported from Norway. Early-onset of PD is 
rare in population-based studies. PD represents a frequent cause of morbidity that 
affects 1–2 per 1000 of the population at any time, clearly most often in the older age 
groups. It affects men slightly more frequently than women. There may be an 
increase in occurrence of the disease that cannot be explained by demographic 
changes of the population alone. It is generally accepted that the prevalence of the 
disease range from 1 to 2 per 1000 in unselected populations and that the disease. 
Most of the increase could be attributed to the general increase in age of the 
population. However, recently published data support an increase in risk of PD, 
especially in men. It was hypothesized that the increase in risk of PD could be 
related to the dramatic changes in smoking behavior that has been taken place 
during the last part of the twentieth century. Increased occurrence of PD has also 
been related to increase in traffic-related air pollution 42, 43. 
2.2.5 DIAGNOSTIC CRITERIA  
          Having established that the patient has Parkinson’s, the (movement disorder 
society) MDS-PD criteria will be applied to determine whether the patient meets 
criteria for PD as the cause of this Parkinson’s. 
Diagnosis of clinically established PD requires: 
1. Absence of absolute exclusion criteria 
2. At least two supportive criteria 
3. No red flags 
Diagnosis of clinically probable PD can be made in: 
1. Absence of absolute exclusion criteria 
2. Presence of red flags counterbalanced by supportive criteria, ie, if one red 
flag is present there must also be at least one supportive criterion; if two red 
flags, at least two supportive criteria are needed. If there are more than two 
red flags, clinically probable PD cannot be diagnosed 44. 
 
 
 
  
2.2.6 DIFFERENTIAL DIAGNOSES  
          Once PD is identified, it is important to consider other conditions in the 
differential diagnosis. As mentioned above, diagnosis of PD is often found to be 
inaccurate at specialty clinics or at postmortem review. Presence of “red-flag” clinical 
features response to levodopa treatment should alert family physicians to the 
possibility of an alternative diagnosis. The main conditions to consider are drug-
induced Parkinson’s, vascular Parkinson’s, progressive supranuclearpalsy, multiple 
system atrophy, and DLB. The diagnosis is normally confirmed by a neurologist. 
Neuroimaging does not have a big role 45. 
 
Figure No 3. Findings suggesting patients need to aneurologist 
2.2.7 TREATMENT OF PD  
         The treatment of PD over the past half century, but levodopa remains the most 
potent drug for controlling PD symptom. Prior to instituting medical therapy, a correct 
diagnosis of PD must be established and the level of impairment (motor, sensory, 
autonomic and mental) determined. Each therapy is to be individualized, and diverse 
drugs other than levodopa are presently available. Among these are the dopamine 
agonists (DA), catechol-o-methyl-transferase (COMT) inhibitors and non 
dopaminergic agents 46. 
 
 
 
  
2.2.7.1 LEVODOPA 
          The introduction of dihydroxyphenylalanine (levodopa) to the treatment of PD 
was a major scientific and clinical breakthrough in the treatment of this devastating 
disease. The enzyme involved in the transformation of levodopa toDA, ie, l-amino 
acid decarboxylase (L-AAD, initially calleddopa decarboxylase) is widespread in the 
body, with high concentrations in the liver. it is essential that levodopa be converted 
into DA in the brain, and so the L-AAD inhibitor should not cross the BBB. The 
inhibition of peripheral L-AAD has another result, which was initially unappreciated: it 
prolongs the biological half-life of levodopa (and therefore also of DA in the brain). 
The pharmacokinetic and pharmacodynamic changes that take place as the disease 
progresses may be major contributors. It has also been speculated that the 
complications may derive, at least in part, from the toxic effects of levodopa or DA 
oxidative metabolites.It quickly became clear also that, of the two dopa isomers, only 
the levorotatory stereoisomer, levodopa, produced therapeutic benefits, and 
chemical means to separate the two isomers were developed. In practice, only 
levodopa is now used in the treatment of PD, resulting in an improved safety profile. 
2.2.7.2 COMT INHIBITORS 
          Catechol-O -methyltransferase (COMT) is a ubiquitous enzyme that breaks 
down levodopa before it can be converted to DA, as well as DA itself. COMT 
inhibitors prolong the availability of a single dose of levodopa, without delaying the 
onset of its effects, frequently reducing the total amount of levodopa needed. 
However, COMT treatment in the earlier stages of PD may also be worthwhile by 
preventing or delaying motor complications. COMT inhibition as a new treatment 
strategy for PD has been recently comprehensively reviewed 46. 
2.2.7.3 DA AGONISTS 
          Dopamine agonists (DA) exert their pharmacologic effect by directly activating 
DA receptors, bypassing the presynaptic synthesis of DA. In order to delay or 
prevent levodopa-induced complications many parkinsonologists recommend using 
DA agonists as the initial or early form of dopaminergic therapy. Dopamine agonists 
(DA) exert their pharmacologic effect by directly activating DA receptors, bypassing 
the presynaptic synthesis of DA.  D2 receptors is important in mediating the 
  
beneficial anti parkinsonian effects of DA agonists, but concurrent D1 and D2 
stimulation is required to produce optimal physiological and behavioral effects.  
2.2.7.4 NONDOPAMINERGIC THERAPY 
           In addition to the dopaminergic drugs, nondopaminergic drugs, such as the 
anticholinergics and amantadine, may provide satisfactory symptomatic relief in early 
phases of anti-PD therapy. A novel antidepressant that enhances noradrenergic and 
serotonergic transmission and acts as a presynaptic alpha-2, 5HT2, and 5HT3 
receptor antagonist has been reported to improve rest tremor and levodopa-induced      
dyskinesia 47. 
2.2.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 
          Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently 
prescribed drugs in modern medicine. NSAIDs are very effective in the alleviation of 
pain, fever and inflammation, and millions of patients worldwide have found relief in 
their use since the discovery of the soothing properties of willow bark more than 
3,500 years ago. NSAID use is however associated with several serious treatment 
side effects, with considerable associated morbidity and mortality. Many of these 
side effects may be prevented by careful consideration of the patient’s risk factors 
and by subsequent implementation of preventive strategies 48. It is generally thought 
that one of their main mechanisms of action is the inhibition of cyclo-oxygenase 
(COX), the enzyme responsible for biosynthesing the prostaglandins and 
thromboxane 49. 
 
Figure No 4. NSAIDs mechanism of action 
  
2.3.1 RISK FACTORS FOR GASTROINTESTINAL COMPLICATIONS OF NSAIDs 
                Dyspeptic symptoms are not a trustworthy warming sign; because of that it 
is important to identify factors that increase the risk of GI events in NSAIDs users. 
Among them, the two main are prior history of complicated ulcers, the most 
important one, and age. Older age is the most common in NSAIDs users and those 
age> 70 years are considered to carry a risk similar to those with history of peptic 
ulcer 50.   
 
2.4 1, 2, 4-Triazin derivative on PD  
Potent, ligand efficient, selective, and orally efficacious 1, 2, 4-Triazin 
derivatives have been identified using structure based drug design approaches as 
antagonists of the adenosine A2A receptor. Structure of ligands to a G protein – 
coupled receptor can be used to direct optimization of novel, low molecular weight 
into high potent and selective lead compounds. In this 1, 2, 4-Triazin derivative 
desirable physicochemical and drug like properties, including high oral bioavailability 
and very potent in vivo efficacy and preclinical candidate for the potential treatment 
of PD. 
 
2.5 DOCKING 
Docking is a method which predicts the preferred orientation of one molecule 
to a second when bound to each other to form a stable complex. Preferred 
orientation helps to predict the strength of association of or binding affinity between 
two molecules. The associations with biological molecules such as proteins, nucleic 
acids, carbohydrates and lipids play an important role in signal transduction i.e. 
agonism or antagonism. So docking is a useful tool for predicting both the strength 
and type of signal produced. 
2.6 MOLECULAR DOCKING 
Molecular docking may be defined as an optimization program, which would 
describe the ‘best-fit’ orientation of a ligand that binds to a particular protein of 
interest. The focus of molecular docking is to computationally stimulate the molecular 
recognition process. The aim of molecular docking is to achieve an optimized 
conformation for both the protein and ligand and relative orientation between protein 
and ligand such that the free energy of the overall system is minimized. Docking 
  
produces plausible candidate structures. These candidates must be ranked by using 
scoring functions and to identify structures that are most likely to occur in nature. 
Calculation of ligand-protein interaction by a scoring function that includes terms and 
equations that describe the intermolecular energies 51. 
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CHAPTER - 3 
DRUG PROFILE 
3.1 DICLOFENAC  
             Diclofenac is a proven, commonly prescribed non steroidal anti-inflammatory 
drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties, and 
has been shown to be effective in treating a variety of acute and chronic pain and 
inflammatory conditions.  
 
Figure No 5. Structure of Diclofenac 
IUPAC Name          : 2-[2-(2, 6-dichloroanilino) phenyl] acetic acid 
Molecular Formula: C14H11Cl2NO2 
Molecular weight   : 296.147g/mol 
Description             : It is a white or almost white crystalline powder 
Melting Point          : 156-158 º C 
Solubility         : It is partially insoluble in water, very slightly soluble in       
ethanol and methyl alcohol 
Category                 :  Non steroidal Anti inflammatory drug 
 
 
  
 
3.1.1 MECHANISM OF ACTION 
Diclofenac belongs to a group of NSAIDs that inhibit both COX-1 and COX-2 
enzymes. The binding of NSAIDs to COX isozymes inhibits the synthesis of 
prostanoids (i.e., prostaglandin [PG]-E2, PGD2, PGF2, prostacyclin [PGI2], and 
thromboxane [TX] A2) 52. PGE2 is the dominant prostanoid produced in inflammation, 
and the inhibition of its synthesis by NSAIDs is believed to be the main mechanism 
of the potent analgesic and anti-inflammatory properties of these agents.  
Although diclofenac is commonly referred to as a traditional NSAID in the 
published literature, these assays have demonstrated that it has a higher selectivity 
for COX-2 than for COX-1, in contrast with most traditional NSAIDs. The degree of 
COX-2 selectivity demonstrated for diclofenac is comparable to that of celecoxib. 
diclofenac is more potent in inhibiting COX-2 than COX-1 isoenzymes. However, the 
estimated IC50 (concentration causing 50 % inhibition of activity) values for COX-1 
and COX-2 of different COX inhibitors have been shown to vary between models 
and selectivity is dose dependent in some cases 53. 
3.1.2 DOSE 
Diclofenac was given orally or by intramuscular injection in doses ranging 
from 50 to 75 mg daily, or up to 150 mg per day for longer-term use. There is no 
evidence that the dosage of diclofenac needs to be modified in patients with the mild 
renal impairment, but as with other NSAIDs caution should be exercised. 
3.1.3 PHARMACOKINETICS  
Absorption of diclofenac is generally rapid and directly proportional to the 
dose. The rate of diclofenac absorption may vary depending on the salt form, 
pharmaceutical composition, and timing of administration in relation to food intake. 
The absorption of diclofenac can be inconsistent, with variable maximum plasma 
concentration (Cmax) and time to Cmax (tmax), as well as the presence of late or 
secondary plasma peaks in plots of diclofenac concentration versus time. It has been 
proposed that these inconsistence’s in diclofenac absorption arise due to individual 
  
subject differences in GI pH, partial precipitation of the dose in the acidic conditions 
in the stomach, variable timing in gastric emptying, and enterohepatic circulation 54. 
Acidic NSAIDs are highly bound to plasma proteins, mainly albumin. 
Diclofenac penetrates into the synovial fluid where the concentrations reach 
approximately 60% of those in plasma. The volume of distribution is approximately 
30L. 
Approximately 60 % of the intact diclofenac reaches the systemic circulation 
due to first-pass metabolism. The main metabolite, 4′-hydroxydiclofenac, is known to 
retain weak anti-inflammatory and analgesic activities. Following biotransformation to 
glucoroconjugated and sulphate metabolites, diclofenac is excreted in the urine. 
Because of its short biological half-life (~2 h) and fast elimination rate (mean 
elimination half-life 1.2–1.8 h), frequent administration of diclofenac is usually 
necessary to maintain its therapeutic concentration, which could in turn increase the 
risk for adverse events 55. 
3.1.4 PHARMACODYNAMICS                     
          Diclofenac directly blocks the PGE2 secretion at the site of inflammation by 
inhibiting      IL-Beta & TNF in the inflammatory cells (intracellular Action). Diclofenac 
has been demonstrated to inhibit cyclooxygenase (COX) activity and to suppress the 
PGE2 production by inflammatory cells, which are likely to be a primary source of 
PGE2. Inflammatory cells release IL-1 and TNF, which produce the PGE2 by 
induction of the COX-2. diclofenac and 4’-hydroxydiclofenac penetrate the 
inflammatory cells like polymorphunuclears, monocytes and rheumatoid synovial 
cells and get hydrolysed to the active metabolites of  diclofenac and 4’-
hydroxyaceclofenac which inhibits IL-1 and TNF released by the inflammatory cells 
and therefore suppress production of PGE2 at the site of inflammation. 
3.1.5 DICLOFENAC SAFETY CONSIDERATIONS 
3.1.5.1 GASTROINTESTINAL CONCERNS 
From their first description, traditional NSAIDs have been associated with GI 
side effects including life-threatening GI hemorrhage. Diclofenac, as discussed 
  
earlier, has more specificity to COX-2 than COX-1, and is associated with a relatively 
low level of GI toxicity compared with the other NSAIDs. Because of purported 
causal relationship between COX-1 inhibition and GI adverse effects, the COX-2-
specific NSAIDs were developed to lower the GI risk 56. 
 
3.1.5.2 CARDIOVASCULAR CONSIDERATIONS 
The COX-2-selective inhibitors were designed to limit the known GI adverse 
events associated with the drug class. However, with the increased use of COX-2 
inhibitors, further analysis of the data, and additional reports, it became clear that 
COX-2-selective inhibitors may be associated with an increase in cardiovascular risk. 
The increased cardiovascular risk associated with COX- 2-selective inhibitors has 
been suggested to be due to a disruption in the normal balance between the 
prothrombotic activity of thromboxane A2 (TXA2) (derived from COX-1 activity) and 
the inhibition of platelet aggregation by PGI2 (derived from COX-2 activity). In other 
words, bleeding or excessive platelet aggregation is hypothesized to occur if this 
balance is tipped toward relatively higher activity of PGI2 or TXA2, respectively. For 
example, it is thought that excessive bleeding associated with traditional NSAIDs is 
due to inhibition of constitutively expressed COX-1 activity (and subsequent 
decrease in platelet aggregation), via a decrease in TXA2, the major product of 
platelet COX-1 57. 
3.1.5.3 RENAL COMPLICATIONS 
In addition to GI and cardiovascular concerns, the prolonged use of NSAIDs 
has been linked to renal injury and toxicity. Although reports have demonstrated that 
selective COX-2 inhibitors have effects on renal function similar to those observed 
with nonselective NSAIDs. Acute treatment with therapeutic doses of diclofenac has 
not been associated with significantly impaired renal function in healthy adults or 
post surgical patients. However, the results from a long-term study (46 months) have 
indicated that prolonged treatment with diclofenac can be associated with decreases 
in creatinine clearance, a predictor in renal dysfunction. Importantly, a time course 
evaluation of decreased clearance revealed that the highest frequency of this 
change occurred in early visits during the treatment period 58, 59. 
 
  
 
3.1.5.4 HEPATIC ADVERSE EFFECTS 
As with antihypertensives, antimicrobials, and immunosuppressants, NSAIDs 
can cause drug-induced liver injury. It has been reported that diclofenac causes 
elevations of transaminase levels more commonly than other NSAIDs. Yet, a review 
of in vitro and in vivo animal studies did not indicate that diclofenac is hepatotoxic. 
While anecdotal reports rarely associate diclofenac with hospitalizations due to liver 
toxicity and acute liver failure, a systemic review of over 60 randomized, controlled 
clinical trials did not associate an increase in clinical liver events with diclofenac 
compared with other NSAIDs. Nonetheless, it is recommended that physicians 
educate their patients on the warning signs of hepatotoxicity, and to minimize 
potential risk by treating patients with NSAIDs with the lowest effective dose for the 
shortest duration. Further, as with other NSAIDs, transaminase levels should be 
measured periodically in patients receiving diclofenac as severe hepatic reactions 
can occur at any time during treatment 60. 
 
3.1.5.5 ADVERSE EVENTS ASSOCIATED WITH TOPICAL FORMULATIONS 
          Topical NSAIDs have been postulated to be as efficacious as oral treatment 
without GI, hepatic and renal side effect complications. As the risk of these events 
increases with age, topical NSAIDs are an attractive option for the treatment of pain 
relief. Overall, reports in the literature regarding adverse events for topical diclofenac 
are limited and details regarding safety are often generalized. Typically reported 
adverse events for topical diclofenac include localized skin reactions including rash, 
itching, or burning. In comparison to oral treatment, topical diclofenac is generally 
well tolerated with a lower incidence of systemic adverse events including GI 
complaints. However, with a limited number of reports summarizing safety of topical 
diclofenac, additional studies are necessary to ascertain any long-term safety risk of 
topical diclofenac specifically or for any safety comparisons with oral formulations. 
Currently, topical formulations of diclofenac carry the same warnings for an 
increased risk of cardiovascular and GI events, as well as renal and hepatic adverse 
effects that are carried by oral formulations of diclofenac and other NSAIDs 61. 
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AIM AND OBJECTIVES 
Parkinson’s disease (PD) is a common neurodegenerative disorder, which is 
characterized by slowly progressive loss of dopaminergic neurons associated with 
substantial morbidity and mortality and the number of persons affected is expected 
to increase dramatically in coming years. 
NSAIDs medications like aspirin, ibuprofen, naproxen, Diclofenac, Mefenamic 
acid, Indomethacin Piroxicam and some selective COX-II inhibitors i.e., Celecoxib 
are one of the commonly used medication for the treatment of Parkinson’s. Among 
this Diclofenac is the most preference drug.  
Several previous studies have suggested that Diclofenac may elicit 
appreciable GI irritation, bleeding and ulceration produced. Synthetic approaches 
based upon chemical modification of Diclofenac have been taken with the aim of 
improving safety profile and in turn therapeutic window. Carboxylic group is a major 
reason for the GI toxicity of Diclofenac, so Structural replacement of carboxyl group 
may reduce the GI toxicity. Previous study reported that 1, 2, 4-Triazin derivative 
may possess appropriate Anti Parkinson’s action. 
Based on that aim of this study is replacement of carboxylic group with 2-
Chloroacetamide to produce the 1, 2, 4 –Triazin derivative of Diclofenac as potential 
ligand for PD 
          Objectives of this study is  
✓ Synthesis of 1, 2, 4-Triazin derivative of Diclofenac by Replacing the 
Carboxylic group with 2-Chloroacetamide.  
✓ Molecular docking studies of 1, 2, 4–Triazin derivative of Diclofenac 
against PD targets. 
✓ Increases the dopamine level against chlorpromazine induced PD rat 
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CHAPTER-5 
PLAN OF WORK 
1. Selection and synthetic scheme of the Diclofenac Analogue 
a) Step I: To Hydrolysis of Diclofenac sodium to 2-[(2, 6-dichloroanilino)   
phenyl]   acetic acid. 
b) Step II: To Synthesis of ethyl-[2-(2, 6-dichloroanilino) phenyl] 
acetate.                 
c) Step III: To Synthesis of [2-(2, 6-dichloroanilino) phenyl] acetic acid    
hydrazide.  
d) Step IV: To Synthesis of 3-{2-[(2, 6-dichlorophenyl) amino] benzyl}-1, 
6-dihydro-1, 2, 4-triazin-5(2H)-one.  
2. Determination of intermediate synthesized compound a, b, c, and d by     
FT-IR. 
3. Molecular docking studies 
4. Acute oral toxicity studies (OECD 423 guidelines) of 1, 2, 4-Triazin 
Analogue of Diclofenac 
5. In vivo Anti Parkinson’s studies 
5.1 Selection of animal 
5.2 Animal grouping  
5.3 Induction of chlorpromazine induced Parkinson’s disease 
5.4 Physical evaluation 
5.4.1 Body weight 
5.4.2 Feed intake 
5.5 Behavioural assessment 
5.5.1 Evaluation of exploratory and locomotors activity by using    
Actophotometer Apparatus 
5.5.2 Evaluation of muscle coordination by using Rota Rod  
5.5.3 Evaluation of cognitive performance by using Morris Water 
Maze Apparatus 
5.5.4 Evaluation of catalepsy 
 
5.6 Biochemical estimation 
  
5.6.1 Estimation of serum glutamate pyruvate (SGPT) 
5.6.2 Estimation of glutamate oxaloacetate transaminase (SGOT) 
5.6.3 Estimation of  Alkaline phosphatase (ALP) 
5.6.4 Estimation of  Total bilirubin  
5.6.5 Estimation of  Urea 
5.6.6 Estimation of  Creatinine          
5.7 Estimation of antioxidant enzyme levels in rat brain 
5.7.1 Estimation of superoxide dismutase (SOD) 
5.7.2 Estimation of reduced glutathione (GSH) 
5.7.3 Estimation of nitrite 
5.7.4 Estimation of protein  
5.7.5 Estimation of lipid peroxidation products  
5.7.6 Estimation of catalase 
5.7.7 Estimation of brain glutamate level 
5.8 Estimation of brain tissue extract neurotransmitters  
             5.7.8 Estimation of brain Ach levels 
             5.7.8 Estimation of dopamine assay  
5.9 Determination of ulcerogenecity  
5.10 Histopathological evaluation 
6  Statistical analysis 
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CHAPTER - 6 
MATERIAL AND METHODS 
6.1 DRUGS AND CHEMICALS 
          All the chemicals used in this study were of analytical grade. The following 
chemicals were used for the experimental study. (Table No. 1) 
Table No 1. Drugs and chemicals 
S.No. MATERIAL SOURCE 
1 Diclofenac Novartis Pvt. Ltd, Hyderabad 
2 Chlorpromazine Suri pharma laboratories Ltd, 
Gujarat 
3 Methanol Loba chemie Pvt. Ltd, Mumbai 
4 Sodium bicarbonate Loba chemie Pvt. Ltd, Mumbai 
5 Hydrazine Hydrate Nice chemicals Pvt.Ltd., Kerala 
6 Dimethylformamide Nice chemicals Pvt.Ltd., Cochin 
7 2-Chloroacetamide Avra Synthesis Pvt.Ltd, Hyderabad 
8 Conc. Sulphuric Acid 98% Loba chemie Pvt. Ltd, Mumbai 
9 Gum acacia Loba chemie Pvt. Ltd, Mumbai 
10 Chloroform chemie Pvt. Ltd, Mumbai 
11 Diethyl ether Loba chemie Pvt. Ltd, Mumbai 
12 Chloroform chemie Pvt. Ltd, Mumbai 
13 Absolute ethanol Changshu hongsheng fine chemical 
co., Ltd, Jiangsu province 
 
 
 
 
 
 
  
6.2 SELECTION AND SYNTHETIC SCHEME DICLOFENAC ANALOGUE 62. 
6.2.1 Step I: Hydrolysis of Diclofenac sodium to 2-[(2, 6-dichloroanilino) 
phenyl] acetic acid.  
           Diclofenac sodium (0.101) was dissolved in ethanol (2.5mol). To this solution 
conc. H2SO4 was added dropwise to hydrolyse the salt to acid. The acid obtained 
was filtered, dried. Yield: 96.34%. (Figure No. 6) 
 
NH
ClCl
COONa COOH
NH
ClClEthanol
Conc.H2SO4
 
Figure No 6. Hydrolysis of Diclofenac sodium to 2-[(2, 6-dichloroanilino) 
phenyl] acetic acid. 
 
6.2.2 Step II: Synthesis of ethyl-[2-(2, 6-dichloroanilino) phenyl] acetate.                 
           0.05 mol of 2-[(2, 6-dichloroanilino) phenyl] acetic acid (Step II) was dissolved 
in absolute ethanol (10ml), conc. H2SO4 (1ml) was added and the reaction mixture 
was refluxed for 22 hrs. Reaction mixture gave on processing ethyl ester. The solid 
obtained was washed with 50 ml of sodium bicarbonate solution (10%) and 
recrystallized from methanol. Yield: 95.14%. (Figure No. 7) 
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Figure No 7. Synthesis of ethyl-[2-(2, 6-dichloroanilino) phenyl] acetate 
 
6.2.3 Step III: Synthesis of [2-(2, 6-dichloroanilino) phenyl] acetic acid 
hydrazide.  
 
          0.01 mol of Synthesis of ethyl-[2-(2, 6-dichloroanilino) phenyl] acetate (Step III) 
and hydrazine hydrate (0.02 mol) were refluxed in absolute ethanol (50ml) for 20hrs. 
The mixture was concentrated, cooled and poured in ice cold water. The solid thus 
precipitated out was filtered, dried and recrystallized from ethanol. Yield: 86.48%. 
(Figure No. 8)  
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Figure No 8. Synthesis of [2-(2, 6-dichloroanilino) phenyl] acetic acid 
hydrazide. 
 
6.2.4 Step IV: Synthesis of 3-{2-[(2, 6-dichlorophenyl) amino] benzyl}-1, 6-
dihydro -1, 2, 4-triazin-5(2H)-one 
          
 0.001 mol of Synthesis of [2-(2, 6-dichloroanilino) phenyl] acetic acid 
hydrazide (Step IV), 2-chloroacetamide (0.001 mol) and dimethylformamide (80 ml) 
were added and the reaction mixture was refluxed for 30 hrs. It was then 
concentrated and cooled, whereupon the solid precipitated was filtered, washed with 
ethanol and recrystallized from DMF. Yield: 79.54%. (Figure No. 9) 
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                Figure No 9. Synthesis of 3-{2-[(2, 6-dichlorophenyl) amino] benzyl}-1, 
6-dihydro -1, 2, 4-triazin-5(2H)-one. 
 
6.3 FT-IR SPECTRA 
  From the all analogue of Diclofenac scheme for the synthesis compounds 
were assigned on the basis of different spectral analysis. In IR spectral studies, the 
synthesized compound I, II, III, IV characteristic contains O-H Stretching, N-H 
Stretching, C-H aromatic stretching, C=O stretching, N-H Bending. 1, 2, 4-Triazine 
derivatives were synthesized in our laboratory.  The all synthesized compounds a, b, 
c, and d was characterized by FTIR. The spectra data were satisfactory to prove the 
structure of compounds. 
 
  
Specifications - Spectral Range: 7000 to 400 cm-1 
➢ Resolution: 1cm-1, 2 cm-1, 4 cm-1, 8 cm-1 
➢ Wave number Repeatability: Better than ±0.01cm-1 
➢ Scanning Speed: 0.2~2.5 cm-1, automatically optimized for detector type 
or manually adjustable for specific applications 
➢ Beam splitter: KBr 
➢ Infrared Source: External, air-cooled, high efficiency Reflex Sphere 
module 
➢ Detector: DTGS, MCT (optional) 
➢ Data system: Compatible computer 
➢ Output: Laser printer 
➢ Software: FT-IR software contains all routines needed for basic 
spectrometer operations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.4 MOLECULAR DOCKING 
6.4.1 Preparation of target  
          Docking is a method by which we can predict the preferred orientation, affinity 
and activity of a molecule to a targeted protein. The structure of the protein-ligand 
complexes for the Parkinsonism Disease associated targets were used for the 
molecular docking studies. They were downloaded from the research collaborator for 
structural bioinformatics (RCSB) Protein data bank (PDB; 
http://www.rcsb.org/pdb/home.do). For each crystal structure, the crystallographic 
water molecule were removed and edited by removing the hetero atoms 63, 64. (Table 
No. 2) 
 
 Table No 2. 1, 2, 4-Triazin derivative of diclofenac against the Parkinson’s 
enzyme targets 
 
 
 
 
 
 
 
 
 
6.4.2 Preparation of ligands 
          Structure of the 1, 2, 4-Triazine derivatives were retrieved. The structure of the 
ligands was drawn in ACD / ChemSketch freeware. Finally, compounds were saved 
in PDB format for further docking studies. 
          1, 2, 4-triazine derivative has desirable physicochemical and drug –like 
properties, including high oral bioavailability and very potent in vivo efficacy. Further 
S.No. NAME OF THE TARGET PDB CODE 
1 Dopamine receptor D3 protein 3PBL 
2 Dopa decarboxylase (DDC) 1JS3 
3 Adenosine A2 receptors (AA2AR) 3EML 
4 P38 map kinase (MPAK) 2ZAZ 
5 Monoamino oxidase-B (MAO-B) 2V5Z 
  
optimization of this 1, 2, 4 triazine derivative of targets has identification of a 
preclinical candidate for the potential treatment of Parkinson’s disease. 65.          
6.4.3 Docking simulation 
          Lamarckian genetic algorithm methodology was employed for docking 
simulations implemented in AutoDock k4. The standard docking procedure was used 
for a rigid protein and flexible ligand whose torsion angles were identified. A grid of 
60, 60, and 60 points in x, y, and z directions was built with grid spacing of 0.375 Å. 
The default settings were used for all other parameters. 
 
 
6.4.4 Analysis and visualization of docking simulation results 
          At the end of the docking, the best poses were analyzed for hydrogen bonding 
and calculation using Discovery studio 4.1 and python software was used to view the 
structure. From molecular docking study estimated by molecular docking score. 
 
6.4.5 Procedure of in silico studies 
❖ Softwares and Databases used 
❖ Accerlys discovery studio viewer 
❖ Molinspiration server 
❖ Accelrys accord for excel 
❖ RCSB protein data bank 
❖ Online SMILES translator 
❖ Autodock 4.2 which combines 
❖ Autodock tools 
❖ Python molecule viewer 1.5.6 
❖ Cygwin 64 
 
6.4.5.1 STEP I: Protein structure refinement  
      3PBL, 1JS3, 3EML, 2ZAZ, 20K, 2V5Z enzyme was downloaded from RCSB 
Protein Data Bank (PDB) and the enzyme was refined before docking. The steps 
involved are: 
❖ Open Accelrys discovery studio viewer. 
❖ FileOpenSelect the enzyme file downloaded from RCSB PDB. 
  
❖ Click View option and then click Hierarchy. 
❖ Click water molecules. 
❖ Click water molecule Select all water moleculescut. 
❖ Select ligand, which is unnecessary and cut. 
❖ Save the molecule in a desired location 
 
6.4.5.2 STEP II: Ligand file format conversion 
❖ The ligands which are desired are drawn in ChemSketch software. 
❖ Tools Click GenerateCick SMILES notation (Simplified Molecular Input 
Line Entry System, which is a file format). 
❖ Save the SMILES in a word document. 
❖ Open the online smiles translator –cactus. nci.nih.gov/services/ translate/ 
❖ Uploadthe SMILES. 
❖ By choosing the required file format and save the file in a pdb format 
(e.g.:ligand.pdb). 
➢ Online smiles translator allows the user to convert SMILES format into PDB, 
MOL, SDF and smile text file format. Thus the selected ligand molecule of 
canonical smile format was converted to pdb format. 
➢ The protein and ligand files which are prepared by above said procedures are 
taken for docking. 
 
6.4.5.3 STEP III: Docking with autodock 4.2 
➢ Docking calculation in AutoDock was performed using the refined protein  
           And the desired ligand in pdb format. 
➢ Preparation and running a docking programme 
 
6.4.5.3.1 Preparing the protein 
➢ Open autodock 4.2 
➢ Open fileClick read moleculeChoose the particular refined enzyme file. 
The elimination of the water is carried by the following steps.  
❖ Press Select option 
❖ Click Selectclick select from string option 
❖ Then write “*HOH*” in the Residue line &“*” in the atom line. 
  
❖ Click AddNo new selection and then dismiss.  
Addition of hydrogens is done by, 
❖ Press Edit option 
❖ Click the Hydrogens 
❖ Then click Add 
❖ Choose all Hydrogen, No Bond Order, and ‘yes’ to renumberingclick Ok. 
➢ Next click edit optionclick add the Kollmann Charges. 
➢ Then save the enzyme molecule as 1ea1refined.pdb 
➢ Select EditDeleteDelete all molecule 
 
6.4.5.3.2 Preparing the ligand 
➢ Confirm that all the hydrogens are added in the ligand. 
➢ Toggle the Auto Dock Tools button. 
➢ Open theLigand Click Input and choose the suitable ligand file and finally 
open. 
The torsions are designed by following steps, 
❖ In the Ligand option select Torsion Tree  
❖ Select Detect Root option 
❖ Click Torsion Tree 
❖ Then select the Choose Torsions option 
❖ Amide bonds should NOT be active. 
➢ After that click the Torsion Tree and select Set Number of Torsions 
➢ Number of rotatable bonds is chosen. 
➢ Finally Save the Ligand files by selecting the Output option (pdbqt file). 
➢ Select EditDeleteDelete all molecule. 
 
6.4.5.3.3 Conversion of pdb files of protein into pdbqt file  
❖ Select the Grid option and open the Macromolecule pdb file. 
❖ Auto Dock adds the Charges and itself merges the Hydrogens. 
❖ Save the object as pdbqt in desired area. 
 
6.4.5.3.4 AutoGrid Calculation and creating “gpf” file 
➢ Open the grid and click Macromolecule option and choose the rigid protein 
then yes to preserve the existing charges.  
  
The Preparation of grid parameter file is carried out by, 
❖ Open Grid 
❖ Select the Set Map Types 
❖ Choose Ligand 
❖ Accept it. 
Setting of grid properties, 
❖ Open Grid 
❖ Experimental Section 
❖ Select the Grid box 
❖ Set the proper Grid Dimensions(60.60.60) 
❖ Adjust the Spacing 
❖ Select the File and click Close Saving Current. 
➢ Save the grid settings as gpf file in the input option (ligand.gpf). 
➢ After running the grid file, the output automatically save as ‘glg’ file 
 
6.4.5.3.5 Auto Dock calculation and creating ‘dpf’ file 
The rigid molecule specification is carried out by, 
❖ Select the Docking option 
❖ Click the Macromolecule  
❖ Set Rigid File Name. 
The ligand specification is carried out by, 
❖ Click the Docking option 
❖ Select the ligand  
❖ And then Accept it. 
➢ In the next step, click Docking option and select Search Parameters in that 
click Genetic Algorithm and finally accept it. 
➢ ClickDocking optionsSelect Docking ParametersChoose the Defaults. 
➢ Click Docking optionSelect Output and adds Lamarckian Genetic algorithm 
(LGA). 
➢ Save the docked settings as ‘dpf’ file in the input option (ligand.dpf) 
➢ After running the docked file, the output automatically saves as ‘dlg’ file. 
 
6.4.5.3.6 Programming of ‘Auto Grid’ and ‘Auto Dock’ execution 
1. Open Cygwin and typed as follows: 
  
➢ cd C: 
➢ cd cygwin 
➢ cd usr 
➢ cd local 
➢ cd bin 
Program should list out the pdb, pdbqt, gpf and dpf files of an enzyme and  
Ligand molecule. 
2. Then type as: 
➢ /autogrid4.exe <space> -p <space>ligand.gpf –l <space>ligand.glg 
If a ligand gets into the spacing of the grid, then the execution of this command will 
be;  
‘Successful completion’. 
3. Then type as: 
➢ /autodock4.exe<space> -p<space>ligand.dpf –l<space>ligang.dlg 
If the ligand binds to the amino acids through 10 different conformations, then the 
execution of this command will be;  
‘Successful completion’. 
 
6.4.6.4 STEP IV: Viewing docking results  
6.4.6.4.1 Reading the docking log file .dlg 
❖ Toggle the AutoDock Tools button 
❖ Click Analyze and Open Dockings. 
❖ In the next step, click Analyze option and Conformations then Load. 
❖ Double click on the conformation for to view it. 
6.4.6.4.2 Visualizing docked conformations 
❖ Click Analyze and Dockings then play. 
❖ Load dlg file  
❖ Choose the suitable conformations 
❖ In the next step, click Analyze and Docking then Show Interactions. 
 
6.4.6.4.3 Obtaining snap shots of docked pose  
❖ Open the File and Read the Molecule  
❖ Open AnalyzeClick Dockings and Open dlg file  
❖ Open AnalyzeClick Macromolecule and Choose pdbqt file. 
  
❖ Open AnalyzeClick Conformations and Load  
❖ Double click the desired conformation 
❖ Click Analyze and Docking then Show Interactions.  
❖ Proteins and ligand interaction will be displayed. Zoom it and increase the 
contrast by holding right key and ctrl. 
❖ Open FileSave imagecygwin/usr/local/bin as.png 
 
6.5. Acute oral toxicity studies (OECD 423 guidelines) of 1, 2, 4-triazin 
derivative 
OECD Guidelines for the Testing of Chemicals are periodically reviewed in 
the light of scientific progress or changing assessment practices. The original 
Guideline 423 was adopted in March 1996 as the second alternative to the 
conventional acute toxicity test, described in Test Guideline 401. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex 
(normally females).  Animals should be fasted prior to dosing with the mouse, food 
but not water should be withheld for 3-4 hours. Following the period of fasting, the 
animals should be weighed and the test substance administered. 
    After the substance has been administered, food may be withheld for a further 
1-2 hours in mice. Three animals are used for each step. The dose level to be used 
as the starting dose is selected from one of four fixed levels, 5, 50, 300 and 2000 
mg/kg body weight. When there is no information on a substance to be tested, for 
animal welfare reasons it is recommended to use the starting dose of 50 mg/kg body 
weight. Animals are observed individually after dosing at least once during the first 
30 minutes, periodically during the first 24 hours, with special attention given during 
the first 4 hours and daily thereafter, for a total of 14 days.  
    Additional observations will be necessary if the animals continue to display 
signs of toxicity. Observations should include changes in skin and fur, eyes and 
mucous membranes, and also cardio vascular system, central nervous systems, 
autonomic nervous and gastro intestinal tract 66, 67. 
  
   Till 14th days observation the animals were out of any side effect, the 1, 2, 4-
Triazin derivative synthesize drug was selected as 1/10 of the dose that was used in 
the treatment group. The doses for in vivo study are selected as 30 mg/kg. (Figure 
No. 10) 
 
Figure No 10. Test procedure with starting dose of 300mg/kg body weight 
 
6.6  IN VIVO ANTI PARKINSON’S STUDIES 
6.6.1 SELECTION OF ANIMALS 
Healthy adult Male Albino Wister Rats (270-350gm) and Female Swiss Albino 
Mice (25-30 gm) will be used for the present study. They are housed in poly 
propylene cages and maintained in an air-conditioned well ventilated animal house 
with standard lab conditions at temperature (25±2ºC), humidity (50±15%) under 12 
  
hour light/dark cycle and were obtained from central animal house of Swamy 
Vivekanandha College of Pharmacy. They are fed with standard pellet diet and water 
ad libitium. All animals used in this study were handled with humane care 
incompliance with the Indian National Science Academy Guidelines for the use and 
care of experimental animals in research and all the animal experiments will be 
performed according to the guidelines prescribed by Committee for the purpose of 
control and supervision on experiments on animals (CPCSEA).  
IAEC Reference No: SVCP/IAEC/PG/1/02/2017 
6.6.2 ANIMAL GROUPING 
  Twenty four Albino Wistar male Rats weighing 250 to 270 gm were randomly 
divided into four groups of six per each. (4 X 6 = 24 Albino Wistar rats). (Table No. 
3) 
 
 
 
 
 
 
 
 
Table No 3. Animal grouping 
S.NO GROUPS 
TREATMENT 
ANIMALS 
REQUIRED 
1 Group I 
(vehicle group) 
Received 1% Gum acacia solution+ Distilled 
water p.o. for 14 days 
6 
2 Group II 
(Negative control 
Received Chlorpromazine 3mg/kg, i.p. 
(dissolved with 1% gum acacia in distilled 
6 
  
group) water suspension) daily for a period of 14 
days 
3 Group III 
(Standard group) 
Received Chlorpromazine (3mg/kg/day),i.p. 
+ Diclofenac (10mg/kg/day) p. o. for 14 days 
6 
4 GroupIV 
(Treatment 
group) 
Received Chlorpromazine (3mg/kg/day), i.p. 
+ 1,2,4-Triazin derivative of Diclofenac at 
dose of 30mg/kg, p. o, respectively for 14 
days 
 
6 
TOTAL NUMBER OF ANIMALS 24 
 
6.6.3 INDUCTION OF CHLORPROMAZINE INDUCED PARKINSON’S  
     Parkinson’s disease was induced by intra peritoneal injection of chlorpromazine 
3mg/kg, i. p (dissolved with 1% gum acacia in distilled water suspension) daily for a 
period of 14 days. Chlorpromazine was administered to all treated groups 30 min 
before the administration of test drug 68. 
 
6.6.4 PHYSICAL EVALUATION: 
6.6.4.1 Body weight 
      Body weight of each rats in all groups were measured weekly till end of the 
treatment using a weighing balance and the changes were recorded. 
 
6.6.4.2 Feed intake 
      Daily feed consumption was measured in individual treatment group by using 
standard weighing balance.  
 
6.6.5 BEHAVIOURAL ASSESSMENT 
            All animals were tested on behavioural activity of rat tests in familiar 
environment was monitored on 0th , 7th and 14st day  after 30 minutes of drug 
treatment. 
a) Evaluation of exploratory and locomotors activity by using Actophotometer 
Apparatus 
  
b) Evaluation of muscle coordination behaviour by using Rota Rod  
c) Evaluation of cognitive performance by using Morris Water Maze Apparatus 
d) Evaluation of catalepsy  
 
6.6.5.1 Evaluation of exploratory and locomotor activity by using 
Actophotometer Apparatus  
          To study the locomotor activity of animal behavior was monitored and 
calculated by using an Actophotometer (activity cage), described by Dews P.B. 
(1953). In this photoelectric cells joined in circuit with a counter. When a beam of 
light falls on the photocell is cut off by the rat, a count is recorded. On the study 0th 
day, 7th day and 14st days the rats from each group were placed individually in the 
activity cage for 10 mins and the scores of each rat was recorded 69. 
6.6.5.2 Evaluation of muscle coordination behaviour by using Rota Rod  
Dunham and Miya (1957) suggested that neurological depression in rats 
could be evaluated by testing their ability to remain on a Rota-rod. Rota-rod 
apparatus is a four panel techno device with timer. Animals (4 at a time) were placed 
on rod rotating at 20-25 rpm speed. Only the rat, which demonstrated their ability to 
remain on the revolving rod (20-25 rpm) for 5 min after training sessions during 
pretest screening, was selected for studies. Decrease in fall off time is suggestive of 
CNS depression. On the study 0th day, 7th day and 14st day the rats from each group 
were fall off time was recorded in all the groups 30 min after drug administration 70, 
71. 
 
6.6.5.3 Evaluation of cognitive performance by using Morris Water Maze 
Apparatus  
          Cognitive abilities were measured by using Morris Water Maze. The chamber 
was a black circular swimming pool of nontoxic materials (160 cm diameter, 80cm 
high and 40 cm deep) and filled with water. Visual cues were placed around the 
chamber. This chamber was divided into four equal quadrants. A square hidden 
black platform (10 cm diameter) was submerged beneath (1.5 cm) the water surface 
in the middle of the target quadrant in the pool. The water is made opaque using 
titanium dioxide suspension and is kept at about 230C ± 20c during experiment. Each 
trial is started from one of four assigned polar positions with a different sequence 
  
each day. The latency to find the platform is measured as the time of placement of 
the rat in the water to the time it finds the platform. On the study 0th day, 7th day and 
14st day the rats from each group were fall off time was recorded in all the groups 30 
min after drug administration 72, 73. 
 
6.6.5.4 Evaluation of catalepsy 
          On the 7th day and 14th day of the experiment the scores were recorded in 
three stages and the scores for each stage was assigned.       
➢ Rat moves normally when placed on the table, score of 0 was given                                                        
➢ In first stage the rat was pushed on the back, if failed to move a score of 0.5 
was given.                                                                                                                                   
➢ For second stage front paws of each rat was placed alternately on 3 cm high 
block. If the rat failed to maintain the forced posture in 10 seconds, a score of 
0.5 for each paw with a total of 1 for this stage was given.                                        
➢ For third stage the front paws of each rat was placed alternately on 9 cm high 
block. If the rat failed to maintain the forced posture in 10 seconds, a score of 
1 for each paw with a total of 2 was added to the scores of first and second 
stage.  
➢ Thus for the single rat, the maximum possible score was 3.5 and that indicate 
the total catalepsy 74. 
6.6.6 BIOCHEMICAL ESTIMATION  
     On 14th day of the study, the animals were anesthetized with diethyl ether. 
The blood was drawn through retro orbital plexus, the serum was obtained after 
centrifugation of total blood without anticoagulants,  at 3000 rpm for 10 min the 
serum was utilization forthe analysis of serum glutamate pyruvate (SGPT), glutamate 
oxaloacetate transaminase (SGOT), Alkaline phosphates, Total bilirubin, Urea, 
Creatinine by standard laboratory techniques 75, 76, 77, 78.     
6.6.7 Estimation of antioxidant enzyme levels in rat brain.  
            On 14th day after behavioural quantification all animals were sacrificed by 
cervical dislocation. The brains were removed, forebrain was dissected out. A 10% 
(w/v) tissue homogenate was prepared in 0.1 M phosphate buffer (pH 7.4) and it was 
used for further estimation of antioxidant level. 
  
a) Estimation of superoxide dismutase (SOD) 
b) Estimation of reduced glutathione (GSH) 
c) Estimation of Nitrite 
d) Estimation of Protein 
e) Estimation of Lipid Peroxidation Products 
f) Estimation of catalase 
g) Estimation of brain glutamate level 
 
6.6.7.1 ESTIMATION OF SUPEROXIDE DISMUTASE (SOD) 
To 1 ml of the sample, 0.25 ml of absolute ethanol and 0.15 ml of chloroform 
were added. After 15 min of shaking in a mechanical shaker, the suspension was 
centrifuged and the supernatant obtained constituted the enzyme extract. The 
reaction mixture for auto-oxidation consisted of 2 ml of buffer, 0.5 ml of 2 mM 
pyrogallol and 1.5 ml of water. Initially the rate of auto-oxidation of pyrogallol was 
noted at an interval of 1 min for 3 min. the assay mixture for the enzyme contained 
2ml of 0.1 M Tris - HCl buffer, 0.5 ml of pyrogallol, aliquots of the enzyme 
preparation and water made up to 4 ml. The rate of inhibition of pyrogallol auto-
oxidation after the addition of the enzyme was noted. The superoxide dismutase 
activity was measured by the inhibition of pyrogallol auto-oxidation at 420 nm for 10 
min. One unit of superoxide dismutase is the amount of enzyme required to bring 
about 50% inhibition of auto-oxidation by pyrogallol. The enzyme activity was 
expressed in terms of units/min/mg protein 79. 
6.6.7.2 ESTIMATION OF REDUCED GLUTATHIONE (GSH) 
1ml of tissue homogenate was precipitated with 1 ml of 10% TCA. The 
precipitate was removed by centrifugation. To an aliquot of the supernatant was 
added 4 ml of phosphate solution and 0.5 ml of 5,5-dithio-bis-(2-nitrobenzoic acid) 
(DTNB) reagent were added and absorbance was taken at 412 nm. The 
concentration of GSH in the supernatant was determined from the standard curve 
using standard reduced glutathione and expressed in nM/mg of protein 80. 
 
6.6.7.3 ESTIMATION OF NITRITE 
The production of nitric oxide (NO) in the brain may occur due to oxidative 
stress and it can be determined by estimation of nitrite level. The nitrite level was 
  
determined spectrophotometrically with Griess reagent (0.1% N-1-naphthyl ethylene 
amine dihydrochloride, 1% sulphanilamide, and 2.5% phosphoric acid). Brain 
homogenate and Griess reagent were mixed equally and this mixture was incubated 
for 10 min and the absorbance was measured at 546nm.The standard curve of 
sodium nitrite was prepared and the concentration of nitrite in the supernatant was 
determined from standard curve 81. 
 
6.6.7.4 ESTIMATION OF PROTEIN  
The protein content of brain tissue was estimated by method described by 
Lowry et al. Standard curve was determined using bovine serum albumin and values 
are expressed in mg/ml 82. 
 
6.6.7.5 ESTIMATION OF LIPID PEROXIDATION PRODUCTS 
Lipid peroxidation was estimated spectrophotometrically in brain tissue by 
quantifying TBARS. In brief, for the estimation of TBARS the supernatant of the 
tissue homogenate was treated with Thio barbituric acid - Tri chloro acetic acid, 
(TBA–TCA) reagent and mixed thoroughly. The mixture was kept in boiling water 
bath for 15 minutes. After cooling, the tubes were centrifuged for 10 minutes and the 
supernatant taken for measurement. The developed colo was read at 532 nm using 
a UV spectrophotometer against a reagent blank. The concentration of TBARS in the 
supernatant was determined from the standard curve using 1, 1, 3, 3-Tetra Methoxy 
Propane (TMP) and expressed in nM/mg of protein 83. 
 
6.6.7.6 ESTIMATION OF CATALASE 
Homogenized the tissue with M/15 phosphate buffer at 1 to 4°C and 
centrifuged. Stirred the sediment with cold phosphate buffer and allowed to stand in 
the cold condition with occasional shaking. Repeat the extraction once or twice, 
supernatants are combined and used for assay. 3 ml of H2O2 phosphate buffer was 
taken in one cuvette added 0.01 – 0.04 ml sample and read against a control cuvette 
containing enzyme solution without H2O2 phosphate buffer at 240nm.∆t was noted 
for a decrease in the optical density from 0.450 to 0.400. This value was used for the 
calculations 84. 
 
6.6.7.7 ESTIMATION OF BRAIN GLUTAMATE LEVEL 
  
 Weighed quantity of brain portion was homogenized with 2 parts by weight of 
perchloric acid and centrifuge for 10 minutes at 3000 rpm. Adjust 3.0ml supernatant 
fluid to pH 9 with 1.0ml phosphate solution. Allow to stand 10 min. in an ice bath and 
then filter through a small, fluted filter paper. Allow to warm to room temperature, 
dilute 1:10 and take 1.0 ml for the assay. Absorbance was measured at 340nm. 
Similarly a blank reading at 340nm was measured. The level of glutamate was 
expressed as μmol/g tissue 85. 
 
6.6.8 ESTIMATION OF BRAIN TISSUE EXTRACT NEUROTRANSMITTERS  
          Examined antioxidant with a help of forebrain, remaining left out brain tissue 
used to analysis neurotransmitters. A 10% (w/v) tissue homogenate was prepared in 
0.1 M phosphate buffer (pH 7.4). The tissue homogenized was taken in 3 ml HCl- 
Butanol in a cool environment. The sample was then centrifuged for 10 min at 2000 
rpm. 0.8 ml of supernatant phase was removed and added to an eppendorf reagent 
tube containing 2 ml of heptane and 0.25 ml 0.1 M HCl. After 10 min, shake the tube 
and centrifuged under same conditions to separate two phases. Upper organic 
phase was discarded and the aqueous phase was used for dopamine assay. 
 
6.6.8.1 Estimation of brain Ach levels 
            To 0.4 ml aliquot of the homogenate is added to a cuvette containing 2.6 ml 
phosphate buffer (0.1M, pH 8) and 100µl of DTNB. The contents of the cuvette were 
mixed thoroughly by bubbling air and absorbance is measured at 412nm in a 
photoelectric colorimeter (H2 grade). When absorbance reaches a stable value, it is 
recorded as the basal reading 5.20 ml of substrate i.e., acetylthiocholine is added 
and change in absorbance is recorded for a period of 10 min at intervals of 2mins. 
Change in the absorbance per minute is thus determined 86. 
 
6.6.8.2 Estimation of dopamine assay  
To 0.02ml of the HCl phase, 0.005 ml 0.4 ml HCl and 0.01ml EDTA/ Sodium 
Acetate buffer (pH 6.9) were added, followed by 0.01 ml iodine solution for oxidation. 
The reaction was stopped after 2 min by the addition of 0.1ml sodium thiosulphate in 
5 M Sodium hydroxide. 10 M Acetic acid was added 1.5 min later. The solution was 
then heated to 100oC for 6 min. When the samples again reach room temperature, 
excitation and emission spectra were read (330 to 375 nm) in a spectrofluorimeter. 
  
Compared the tissue values (fluorescence of tissue extract minus fluorescence of 
tissue blank) with an internal reagent standard (fluorescence of internal reagent 
standard minus fluorescence of internal reagent blank). Tissue blanks for the assay 
were prepared by adding the reagents of the oxidation step in reversed order 
(sodium thiosulphate before iodine). Internal reagent standards were obtained by 
adding 0.005 ml bidistilled water and 0.1 ml HCl Butanol to 20 ng of dopamine 
standard 87. 
 
 
6.6.9 DETERMINATION OF ULCEROGENECITY 
At the end of the study stomach of the entire animals were cut opened and 
the ulcerogenecity was asseses by ulcer score as follows. 
0-Normal Mucosa, 
0.5-Red coloration, 
1.0-Spot ulcers, 
1.5-Hemorrhagic streaks, 
2.0-Ulcers >3 but <5,  
2.5- Ulcer >5. 
 
6.6.10 HISTOPATHOLOGICAL EVALUATION  
     All the animals were sacrificed ay the end of the experiments. substantia 
nigra region of brain was removed of all the animals and post fixed in formal saline 
(24 hrs) washing was done in tape water then serial dilution (methyl, ethyl and 
absolute) were used to dehydration. Specimens were cleared in xylene and 
embedded in paraffin at 56º c in hot air oven for 24 hrs. Blocks were prepared by 
using paraffin wax at 4µm thick in microtone. The obtained tissue section were 
deparaffinized and stained by hematoxylin and eosin (H&E) stain for 
histopathological examination through the light microscope 88. 
6.7 STATISTICAL ANALYSIS  
          The statistical analyses were carried out using SPSS version 20.0 for 
Windows. Behavioral comparisons of pre- and post treatment four groups of data 
were analyzed using three way analysis of variance (ANOVA) followed by scheffe 
test for comparisons between various treated groups. The results were presented as 
  
means ± SEM, n=6. Values with p<0.05 were considered to be statistically significant 
89. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter-7 
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CHAPTER 7 
RESULT 
7.1 Synthetic Scheme of Designed Compounds 
 2-[(2, 6-dichloroanilino) phenyl] acetic acid (a) was prepared from Diclofenac 
sodium by hydrolysis in the presence of conc.H2SO4 and ethanol. Ethyl - [2-(2, 6-
dichloroanilino) phenyl] acetate (b) was prepared from Compound a by etherification 
in the presence of conc. H2SO4 and ethanol. [2-(2, 6-dichloroanilino) phenyl] acetic 
acid hydrazide (c) was prepared from Compound b by Treatment with Hydrazine 
Hydrate in Absolute Ethanol. The reaction of Compound c was refluxed with 2-
Chloroacetamide and Dimethylformamide to yield 3-{2-[(2, 6-dichlorophenyl) amino] 
benzyl}-1, 6-dihydro-1, 2, 4-triazin-5(2H)-one. (d) (Figure No.: 11) 
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Figure No.: 11 Synthesis of 3-{2-[(2, 6-dichlorophenyl) amino] benzyl}-1, 6-
dihydro -1, 2, 4-triazin-5(2H)-one. 
 
  
7.2 FT-IR Analysis of Diclofenac Analogues 
Compound a: The IR interpretation of 2-[(2, 6-dichloroanilino) phenyl] acetic 
acid. IR (KBr), v, cm-1: 3100-3000 (CH), 1795.60 (C=O), 3469.70 (O-H), 1419.51 (C-
O-H), 3095.54 (N-H), 1367.44 (C-N), 2509.22 (CH2). (Figure No.: 12) 
 
Figure No.: 12 IR spectrum of compound-a (2-[(2, 6-dichloroanilino) phenyl] 
acetic acid) 
 
 
 
 
  
Compound b: The IR interpretation of ethyl - [2-(2, 6-dichloroanilino) phenyl] 
acetate. IR (KBr), v, cm-1: 3307.69 (CH), 1720.39 (C=O), 1238.21 (C-O-H), 3417.63 
(N-H), 1326.93 (C-N), 2981.74 (CH2), 482.17 (C-Cl). (Figure No.: 13) 
 
 
Figure No.: 13 IR spectrum of compound-b ethyl - [2-(2, 6-dichloroanilino) 
phenyl] acetate 
 
 
 
 
  
Compound c: The IR interpretation of [2-(2, 6-dichloroanilino) phenyl] acetic 
acid hydrazide. IR (KBr), v, cm-1: 3056.96 (CH), 1488.94 (C=Cl), 1731.96 (C=O), 
3450.41 (NH), 1240 (C-N), 3417.63 (N-H), 1326.93 (C-N), 1488.94 (CH2), 455.03 (C-
Cl). (Figure No.: 14) 
 
 
Figure No.: 14 IR spectrum of compound-c [2-(2, 6-dichloroanilino) phenyl] 
acetic acid hydrazide 
 
  
 
Compound d: The IR interpretation of IR (KBr), v, cm-1: 3056.96 (CH), 
1488.94 (C=Cl), 1731.96 (C=O), 3450.41 (NH), 1240 (C-N), 3417.63 (N-H), 1326.93 
(C-N), 1488.94 (CH2), 455.03 (C-Cl). (Figure No.: 15) 
Figure No.: 15 IR spectrum of compound-d 3-{2-[(2, 6-dichlorophenyl) amino] 
benzyl}-1, 6-dihydro-1, 2, 4-triazin-5(2H)-one. 
In this above synthesized Compounds a, b, c and d entire IR spectra region 
used to identification the functional group. The compounds showed the possible IR 
(KBr), v, cm-1: CH, C=O, C-O-H, N-H, C-N, CH2, C-Cl shows the presence of the 
functional group. 
  
7.3 Molecular Docking studies of 1, 2, 4-Triazin derivative of diclofenac on 
Molecular Docking  
Structure of 1, 2, 4- Triazin derivative of Diclofenac was drawn by using 
chemoffice 2004 software and docking simulation was carried out against the 
Parkinson’s enzyme targets like Dopamine receptor D3 protein (3PBL), (Figure No 
.16) Dopa decarboxylase-DDC (1JS3), (Figure No .17) Adenosine A2 receptor-
AA2AR (3EML), (Figure No .18) P38 map kinase (2ZAZ), (Figure No .19) 
Monoamino oxidase-B-MAO-B (2V5Z) (Figure No .20) enzymes target with the help 
of Autodock k4 program. The binding scores of designed ligand was 1-10 scores 
with D3 protein, DDC, AA2AR, MAPK and MAO-B enzymes ranging from -6.35 to -
5.64 Kcal/mol, -6.86 to -5.81 Kcal/mol, -6.11 to -5.02, -8.67 to -4.63 Kcal/mol, and -
10.25 to -6.76 Kcal/mol respectively. (Table No. 4) 
 
Table No.: 4 Docking scores for 1, 2, 4-Triazin derivative of diclofenac against 
the Parkinson’s enzyme targets 
Target  Name PDB Code Docking Score (Kcal/Mol) 
Dopamine receptor D3 protein 3PBL -6.35 to -5.64 
Dopa decarboxylase (DDC) 1JS3 -6.86 to -5.81 
Adenosine A2 receptor (AA2AR) 3EML -6.11 to -5.02 
P38 map kinase (MAPK) 2ZAZ -8.67 to -4.63 
Monoamino oxidase-B (MAO-B) 2V5Z -10.25 to -6.76 
 
  
 
Figure No.: 16 Docking study of 1, 2, 4-Triazin derivative of diclofenac against 
3PBL targets 
 
Figure No.: 17 Docking study of 1, 2, 4-Triazin derivative of diclofenac against 
1JS3 targets 
  
 
Figure No.: 18 Docking study of 1, 2, 4-Triazin derivative of diclofenac against 
3EML targets 
 
Figure No.: 19 Docking study of 1, 2, 4-Triazin derivative of diclofenac against 
2ZAZ targets 
  
 
Figure No.: 20 Docking study of 1, 2, 4-Triazin derivative of diclofenac against 
2V5Z targets 
 
 
 
 
 
 
 
 
 
 
 
  
7.4 Effect of 1, 2, 4-Triazin Derivative on Changes in Acute Oral Toxicity 
Studies 
The 1, 2, 4-Triazin derivative compound not produced any toxic symptoms or 
mortality up to dose level of 300mg/kg orally in mice and hence, the drugs were 
considered safe for further pharmacological screening. As per OECD-423 1/10 
(30mg/kg) of 1, 2, 4-Triazin derivative was used for future pharmacological 
screening. No lethal toxic reactions were observed until the end of the 14 days. 
(Table No.: 5) 
Table No.: 5. Acute oral toxicity study of 1, 2, 4-Triazin derivative of Diclofenac 
S. 
No 
Symptoms 1, 2, 4-Triazin Derivative 
Compound (30mg/Kg, p. o) 
1.  Depth of breathing -- 
2.  Abdominal breathing -- 
3.  Gasping -- 
4.  Tachyphea -- 
5.  Bradycardia -- 
6.  Tachycardia -- 
7.  Convulsion -- 
8.  Somnolence ++ 
9.  Loss of righthing refleux -- 
10.  Catalepsy -- 
11.  Unusual locomototion -- 
12.  Sedation -- 
13.  Salivation -- 
14.  Droping feces -- 
15.  Dieresis hematuria -- 
 
 
  
7.5 Effect of the 1, 2, 4-Triazin derivative of diclofenac on Changes in Body 
Weight  
On this study, final body weight of chlorpromazine Group II showed 
significantly (P<0.05) decrease in body weight when compare to control Group I.  
Group III showed mild significant (P<0.05) increase in body weight when compared 
to the Group II. The treatment Group IV are more significant (P<0.001) increases 
when compared to Group II. (Table No.: 6) 
7.6 Effect of 1, 2, 4-Triazin derivative of diclofenac on Feed Intake in 
Chlorpromazine Induced Parkinson’s Rat 
In this study, Feed intake Group II was significantly decreased when 
compared to control group (Group I). The Diclofenac group (Group III) and treatment 
Group shows significantly increase in feed intake when compared to Group II. (Table 
No.: 7) 
7.7 Effect of 1, 2, 4-Triazin derivative of diclofenac on Exploratory and 
Locomotor Activity by Using Actophotometer in Chlorpromazine Induced 
Parkinson’s Rat 
Chlorpromazine group showed significantly (P<0.05) decrease in locomotor 
activity when compared to the control group. Diclofenac Group III shows significantly 
increases when compared to chlorpromazine Group II. In this no significant 
difference in treatment Group IV on the 7th day 
On the 14th day, Diclofenac Group III shows significantly (P<0.05) increase 
when compared to control Group I. Treatment Group IV exhibited (P<0.001) 
significantly increases when compared to chlorpromazine Group II and Diclofenac 
Group III. (Table No.:  8) 
7.8 Effect of The 1, 2, 4-Triazin derivative of diclofenac on Muscle Coordination 
Behaviour by Using Rota Rod in Chlorpromazine Induced Parkinson’s Rat 
The mean fall- off time of Group I animals from the rota rod was observation 
of the treatment. On the 7th day Group II showed significantly (P<0.05) decrease 
when compare to the control Group I. treatment group IV shows significantly 
(P<0.001) when compared to the chlorpromazine Group IV. 
  
On the 14th day chlorpromazine Group II showed significantly (P<0.001) 
decreased when compare to the control Group I. Diclofenac group III showed 
significantly (P<0.001) increased when compare to the chlorpromazine Group II. 
Treatment Group IV showed significantly (P<0.001) increases when compare to the 
chlorpromazine Group II. (Table No.: 9) 
7.9 Effect of The 1, 2, 4-Triazin derivative of diclofenac on Cognitive 
Performance by Using Morris Water Maze in Chlorpromazine Induced 
Parkinson’s Rat 
Antipsychotic related effects on swim speeds on the 7th day chlorpromazine 
Group II showed significantly (P<0.05) increased when compared to control Group I. 
Group III showed significant (P<0.05) decreased when compared to Chlorpromazine 
Group II. Treatment Group IV showed significantly (P<0.001) increase when 
compared to the chlorpromazine Group II. 
On the 14th day chlorpromazine Group II showed significantly (P<0.01) 
increased when compared to the control Group I. Diclofenac Group III showed 
significantly (P<0.001) decreased when compared to the chlorpromazine Group II. 
Treatment Group IV showed significantly (P<0.001) decreased when compared to 
chlorpromazine Group II. (Table No.: 10) 
7.10 Effect of The 1, 2, 4-Triazin derivative of diclofenac on Catalepsy in 
Chlorpromazine Induced Parkinson’s Rat 
On 7th day chlorpromazine Group II showed significantly (P<0.001) increased 
when compared to control Group I. Diclofenac Group III shows significantly 
(P<0.001) decreased when compared to chlorpromazine Group II. Treatment Group 
IV showed significantly (P<0.001) decreased when compared to chlorpromazine 
Group II.  
On 14th day chlorpromazine Group II showed significantly (P<0.001) 
increased when compared to control Group I. Diclofenac Group III shows 
significantly (P<0.001) decreased when compared to chlorpromazine Group II. 
Treatment Group IV showed significantly (P<0.001) decreased when compared to 
chlorpromazine Group II. (Table No.: 11) 
  
7.11 Effect of 1, 2, 4-Triazine derivative of diclofenac on biochemical parameter 
In Chlorpromazine Induced Parkinson’s Rat 
In this study, serum glutamate pyruvate (SGPT), glutamate oxaloacetate 
transaminase (SGOT), Alkaline phosphates, Total bilirubin, was of chlorpromazine 
Group II showed significantly (P<0.001) increase in SGPT, SGOT, ALP, Total 
bilirubin  level when compared to control Group I. In the 1, 2, 4-Triazin treatment 
group shows significantly low level when compared to the Diclofenac Group. (Table 
12) 
7.12 Effect of 1, 2, 4-Triazine derivative of diclofenac on superoxide dismutase 
(SOD) in Chlorpromazine Induced Parkinson’s Rat 
In this study, SOD of chlorpromazine Group II showed significantly (P<0.001) 
decreases in SOD level when compared to control Group I. Diclofenac Group III 
showed significantly (P<0.01) increases in SOD level when compared to 
chlorpromazine Group II. The treatment Group IV showed significantly (P<0.01) 
increases in SOD level when compared to chlorpromazine Group II. (Table 13) 
7.13 Effect of 1, 2, 4-Triazine derivative of diclofenac on reduced glutathione 
(GSH) in Chlorpromazine Induced Parkinson’s Rat 
In this study, GSH of chlorpromazine Group II showed significantly (P<0.001) 
decreases in GSH level when compared to control Group I. The treatment Group IV 
showed significantly (P<0.001) increases in GSH level when compared to control 
Group I. Diclofenac Group III showed significantly (P<0.001) increase in SOD level 
when compared to chlorpromazine Group II. Treatment Group IV showed 
significantly (P<0.05) increase in SOD level when compared to Diclofenac Group III. 
(Table 13) 
7.14 Effect Of 1, 2, 4-Triazine derivative of diclofenac on nitrite in 
Chlorpromazine Induced Parkinson’s Rat 
             In this study, nitrite of chlorpromazine Group II showed significantly              
(P<0.01) increase in nitrite level when compared to control Group I. Diclofenac 
Group III showed significantly (P<0.05) decrease in nitrite level when compared to 
chlorpromazine Group II. Treatment Group IV showed significantly (P<0.001) 
decrease in nitrite level when compared to chlorpromazine Group II. (Table 13) 
  
7.15 Effect of 1, 2, 4-Triazine derivative of diclofenac on protein in 
Chlorpromazine Induced Parkinson’s Rat 
           In this study, protein of chlorpromazine Group II showed significantly               
(P<0.001) decrease in protein level when compared to control Group I. Diclofenac 
Group III showed significantly (P<0.01) increase in protein level when compared to 
chlorpromazine Group II. Treatment Group IV showed significantly (P<0.001) 
increase in protein level when compared to chlorpromazine Group II. (Table 13) 
7.16 Effect of 1, 2, 4-Triazine derivative of diclofenac on lipid peroxidation 
products in Chlorpromazine Induced Parkinson’s Rat 
           In this study, lipid peroxidation of Diclofenac Group III showed significantly     
(P<0.01) increase in lipid peroxidation level when compared to chlorpromazine 
Group II. Treatment Group IV showed significantly (P<0.05) decrease in lipid 
peroxidation level when compared to chlorpromazine Group II. And Group I and 
Group II showed no significant difference in lipid peroxidation level when compared 
to control Group I. (Table 13) 
7.17 Effect of 1, 2, 4-Triazine derivative of diclofenac on catalase in 
Chlorpromazine Induced Parkinson’s Rat 
   In this study, catalase of Chlorpromazine Group II showed significantly 
(P<0.001) decrease in catalase level when compared to control Group I. Treatment 
Group IV showed significantly (P<0.05) increase in catalase level when compared to 
control Group I. And then Diclofenac Group III and chlorpromazine Group II showed 
significant (P<0.001) decreases in catalase level when compared to Diclofenac 
Group II.  (Table 13) 
7.18 Effect of 1, 2, 4-Triazine derivative of diclofenac on brain glutamate level 
in Chlorpromazine Induced Parkinson’s Rat 
In this study, brain glutamate level of Chlorpromazine Group II showed 
significantly (P<0.01) increases when compared to control Group I. Diclofenac group 
III showed significantly (P<0.001) decrease when compared to control Group I. 
Treatment Group IV showed significantly (P<0.001) decrease when compared to 
control Group I. Diclofenac Group III showed significantly (P<0.001) increases when 
compared to Chlorpromazine Group II. Treatment Group IV showed significantly 
(P<0.01) increase when compared chlorpromazine Group II. (Table 13) 
  
7.19 Effect of 1, 2, 4-Triazin derivative of diclofenac on Brain Ach Levels in 
Chlorpromazine Induced Parkinson’s Rat 
 In this brain acetylcholine chlorpromazine group showed significantly (P<0.01) 
increase when compared to control group. Treatment group showed significantly 
(P<0.05) decrease when compare to Chlorpromazine group. Diclofenac group 
showed no significant difference when compared to control group. (Table 14) 
7.20 Effect Of 1, 2, 4-Triazin derivative of diclofenac on Dopamine Assay in 
Chlorpromazine Induced Parkinson’s Rat 
The dopamine level in chlorpromazine animals were reduced significantly      
(P<0.001) decrease when compared to control Group I. Treatment Group IV showed 
significantly (P<0.001) increase when compared to Diclofenac Group II. And then 
Treatment Group IV showed significantly (P<0.01) increase when compared to 
chlorpromazine Group III. (Table 14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7.21 Effect of 1, 2, 4-Triazin derivative of diclofenac on Determination of 
Ulcerogenecity in Chlorpromazine Induced Parkinson’s Rat 
            In ulcerogenecity chlorpromazine induced Group II shows ulcer score 
denoted as 0.5. In this Diclofenac Group III shows ulcer score was increased were 
denoted as 2.0. Treatment Group IV and control Group I shows ulcer score was 
denoted as normal 0. (Figure No. 21) 
                    
                   GROUP I                                                                GROUP II 
 
                    
                   GROUP III                                                              GROUP IV 
 
Figure No.: 21 Effect of 1, 2, 4-triazin derivative of diclofenac on determination 
of ulcerogenecity in chlorpromazine induced parkinson’s rat 
 
 
 
 
 
  
 
7.22 Histopathological evaluation 
          Histopathology of our samples showed that chlorpromazine caused 
degeneration in the mid brain region of the rats as neurons were under oxidative 
stress when compared with normal rats as can be seen from Presence of hyper 
chromatic nuclei with eosinophilic vacuolated cytoplasm in edematous. However 
sections examined from 1, 2, 4-Triazin derivative treated group shows exhibits intact 
architecture with occasional hyperchromatic nuclei and mild vacuolization suggestive 
of mild degenerative changes in treated animals. (Figure No. 22) 
   
                                                           
                 CONTROL GROUP                                    DICLOFENAC GROUP 
 
 
                          
        CHLORPROMAZINE GROUP                 1, 2, 4- TRIAZIN TEATMENT GROUP 
Figure No.: 22 Histopathological evaluations 
 
  
Table No.: 6 Effect of 1, 2, 4-triazin derivative of diclofenac on changes in body 
weight in chlorpromazine induced Parkinson’s rat 
 
TREATMENT INITIAL BODY WEIGHT (g) FINAL BODY WEIGHT (g) 
Group I 
(vehicle group) 
 
240.0 ± 10.33 
 
266.7 ± 10.22 
Group II 
(Negative group) 
 
240.0 ± 12.65 
 
216.7 ± 10.54 a* 
Group III 
(Standard group) 
 
243.3 ± 11.16 
 
256.7 ± 11.45 b* 
Group IV       
(treatment group) 
 
251.7 ± 12.49 
 
280.0 ± 12.91 b*** 
 
Values are expressed as mean ± SEM, n=6,  
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
 
Graph No.: 1 Effect of 1, 2, 4-Triazin derivative of diclofenac on Changes in 
Body Weight in Chlorpromazine Induced Parkinson’s Rat 
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Table No.: 7 Effect of 1, 2, 4-Triazin derivative of diclofenac on Feed Intake in 
Chlorpromazine Induced Parkinson’s Rat 
 
Treatment Initial Feed Intake (g) Final Feed Intake (g) 
Group I                             
(vehicle group) 
90 100 
Group II                     
(Negative group) 
70 50 
Group III                       
(Standard group) 
80 90 
Group IV                  
(treatment group) 
90 110 
 
 
Graph No.: 2 Effect of 1, 2, 4-Triazin derivative of diclofenac on Feed Intake in 
Chlorpromazine Induced Parkinson’s Rat 
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Table No.: 8 Effect of 1, 2, 4-Triazin derivative of diclofenac on Exploratory and 
Locomotors Activity by Using Actophotometer in Chlorpromazine Induced 
Parkinson’s Rat 
 
TREATMENT 0th day 7th day 14th day 
GroupI             
(vehicle group) 
 
112.7 ± 11.79 
 
120.3 ± 12.21 
 
113.0 ± 11.42 
GroupII       
(Negative group) 
 
126.7 ± 10.13 
 
73.17 ±  6.45 
 
78.17 ± 1.88a* 
GroupIII 
(Standard group) 
 
118.5 ± 11.53 
 
95.50 ± 11.90a* 
 
82.00 ± 4.68a* 
GroupIV 
(treatment group) 
 
129.0 ± 10.36 
 
130.0 ± 12.48b* 
 
149.2±11.71b*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
 
Graph No.: 3 Effect of 1, 2, 4-Triazin derivative of diclofenac on Exploratory 
and Locomotors Activity by Using Actophotometer in Chlorpromazine Induced 
Parkinson’s Rat 
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Table No.: 9 Effect of 1, 2, 4-Triazin derivative of diclofenac on Muscle 
Coordination Behaviour by Using Rota Rod in Chlorpromazine Induced 
Parkinson’s Rat 
 
TREATMENT 0th day 7th day 14th day 
Group I 
(vehicle group) 
 
116.7 ± 13.80 
 
123.0 ±  10.78 
 
138.7 ±  13.40 
Group II 
(Negative group) 
 
119.0 ± 11.62 
 
91.0 ± 3.23a* 
 
66.33±5.83a*** 
Group III 
(Standard group) 
 
99.33 ± 7.41 
 
124.2 ± 10.53 
 
142.7 ± 11.50b*** 
Group IV 
(treatment group) 
 
113.5 ± 10.29 
 
125.0±11.00b*** 
 
140.7 ± 13.35b*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
 
Graph No.: 4 Effect of 1, 2, 4-Triazine derivative of diclofenac on muscle 
coordination behaviour by using Rota Rod in chlorpromazine induced 
Parkinson’s rat 
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Table No.: 10 Effect of the 1, 2, 4-triazin derivative of diclofenac on cognitive 
performance by using morris water maze in chlorpromazine induced 
Parkinson’s rat 
 
TREATMENT 0th day 7th day 14th day 
Group I (vehicle 
group) 
 
29.01  ± 1.90 
 
29.67 ± 1.88 
 
26.63 ± 1.43 
Group II (Negative 
control group) 
 
23.43  ± 2.71 
 
35.95 ± 1.27a* 
 
36.99 ± 1.13a*** 
Group III 
(Standard group) 
 
25.65 ± 1.51 
 
27.99 ± 1.98b* 
 
27.21 ± 1.91b*** 
Group IV 
(treatment group) 
 
28.82 ± 1.60 
 
24.45±1.25b*** 
 
25.02 ± 1.03b*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
 
Graph No.: 5 Effect of the 1, 2, 4-Triazin derivative of diclofenac on Cognitive 
Performance by Using Morris Water Maze in Chlorpromazine Induced 
Parkinson’s Rat 
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Table No.: 11 Effect of the 1, 2, 4-triazin derivative of diclofenac on catalepsy in 
chlorpromazine induced Parkinson’s rat 
 
TREATMENT 0th day 7th day 14th day 
Group I (vehicle 
group) 
 
20.17 ± 3.08 
 
16.83 ± 1.77 
 
16 ± 1.82 
Group II (Negative 
control group) 
 
234.3 ± 14.49 
 
265.3±13.29a*** 
 
351.2 ± 
15.46a*** 
Group III 
(Standard group) 
 
32.33 ± 1.08 
 
31.00 ± 1.96b*** 
 
24.33 ± 
3.28b*** 
Group IV 
(treatment group) 
 
27.50 ± 1.40 
 
28.20 ± 1.67b*** 
 
13.17 ± 
0.94b*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
 
Graph No.: 6 Effect of 1, 2, 4-Triazin derivative of diclofenac on catalepsy in 
Chlorpromazine Induced Parkinson’s Rat 
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Table No.: 12 Effect of 1, 2, 4-triazine derivative of diclofenac on biochemical parameter in chlorpromazine induced 
Parkinson’s rat 
 
TREATMENT 
 
SGPT 
(IU/L) 
 
SGOT 
(IU/L) 
 
ALP 
(IU/L) 
 
BILIRUBIN 
(mg/dl) 
 
Urea 
(mg/dl) 
 
CREATININE 
Group I 
(vehicle group) 
49.89 ± 3.27 17.99 ± 2.92 80.25± 8.04 0.158±0.01 12.68±1.91 0.5117±0.07 
Group II 
(Negative control 
group) 
75.17 ±9.79a* 38.24 ± 8.47a* 142.7± 4.39a*** 0.681±0.08a*** 20.94±1.30a** 0.9117±0.02a** 
Group III 
(Standard group) 
64.64 ± 4.77 32.91 ± 4.05 97.32± 2.82 0.1967±0.02 20.24± 1.05a** 0.805±0.07a* 
Group IV(treatment 
group) 
46.80 ± 2.04b* 17.30 ± 2.96b* 
60.73± 6.96a***, 
b*** 
0.1317±0.01a***, 
b*** 
12.74± 1.70b** 0.4217±0.06b*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
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Graph No.: 7 Effect of 1, 2, 4-Triazine derivative of diclofenac on Serum 
Glutamate Pyruvate (SGPT) in chlorpromazine induced Parkinson’s rat 
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Graph No.: 8 Effect of 1, 2, 4-Triazine derivative of diclofenac on glutamate 
oxaloacetate transaminase (SGOT) in chlorpromazine induced Parkinson’s 
rat 
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Graph No.: 9 Effect of 1, 2, 4-Triazine derivative of diclofenac on Alkaline 
phosphates in chlorpromazine induced Parkinson’s rat 
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Graph No.: 10  Effect of 1, 2, 4-Triazine derivative of diclofenac on Total 
bilirubin in chlorpromazine induced Parkinson’s rat 
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Graph No.: 11 Effect of 1, 2, 4-Triazine derivative of diclofenac on urea in 
chlorpromazine induced Parkinson’s rat 
 
G
ro
up
 I
G
ro
up
 II
G
ro
up
 II
I
G
ro
up
 IV
0.0
0.2
0.4
0.6
0.8
1.0
CREATININE
m
g
/d
l
 
Graph No.: 12 Effect of 1, 2, 4-Triazine derivative of diclofenac on Creatinine 
in chlorpromazine induced Parkinson’s rat 
 
  
Table No.: 13 Effects of 1, 2, 4-triazin derivative of diclofenac on antioxidant 
enzyme levels in rat brain 
 
TREATMEN
T 
SOD 
(UNITS/M
L) 
GSH 
(Umol/L) 
NITRITE 
(m mol/l) 
PROTEIN 
(mg/dl) 
LIPID 
PEROXIDA
SE 
(µmol\L) 
CATAL
ASE 
(mg/dl) 
GLUTAM
ATE 
(mg/dl) 
Group I 
(vehicle 
group) 
205.2 
±10.22 
4.417±0.23 
3.670 
±0.25 
0.6583± 
0.05 
1.665±0.18 
272.8± 
15.16 
12.09± 0.82 
Group II 
(Negative 
control 
group) 
129.5 
±10.00a*** 
2.003±0.21
a** 
60.74 ± 
3.82a** 
0.2050±0.0
5a*** 
2.336±0.22a
* 
189.8±12
.92a*** 
16.93± 
1.08a** 
Group III 
(Standard 
group) 
201.5 ± 
12.25b** 
5.877±0.69
a***,b*** 
6.280 ± 
1.29a*** 
0.6733±0.0
5 a*** 
0.8133±0.27
a**, b*** 
243.3± 
8.99b* 
5.588± 
0.83a***b**
* 
GroupIV 
(treatment 
group) 
220.0 ± 
13.55b*** 
8.028±0.43
a** 
3.467 ± 
0.74a*** 
0.8300±0.0
1 b*** 
1.152±0.36a
***, b*** 
327.8±5.
07a*,b*** 
3.577± 
0.77a*** 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, III, IV b- Group II VS III, and IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05  
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Graph No.: 13 Effect of 1, 2, 4-Triazine derivative of diclofenac on 
superoxide dismutase in chlorpromazine induced Parkinson’s rat 
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Graph No.: 14 Effect of 1, 2, 4-Triazine derivative of diclofenac on reduced 
glutathione (GSH) in chlorpromazine induced Parkinson’s rat 
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Graph No.: 15 Effect of 1, 2, 4-Triazine derivative of diclofenac on Nitrite in 
chlorpromazine induced Parkinson’s rat 
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Graph No.: 16 Effect of 1, 2, 4-Triazine derivative of diclofenac on protein in 
chlorpromazine induced Parkinson’s rat 
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Graph No.: 17 Effect of 1, 2, 4-Triazine derivative of diclofenac on Lipid 
Peroxidase in chlorpromazine induced Parkinson’s rat 
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Graph No.: 18 Effect of 1, 2, 4-Triazine derivative of diclofenac on Catalase 
in chlorpromazine induced Parkinson’s rat 
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Graph No.: 19  Effect of 1, 2, 4-Triazine derivative of diclofenac on glutamate 
level in chlorpromazine induced Parkinson’s rat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table No.: 14 Effects of 1, 2, 4-Triazin Derivative of diclofenac on Brain Ach 
Levels in Rat Brain 
 
Values are expressed as mean ± SEM, n=6 
Comparisons were made between a-Group I VS II, b- Group II Vs IV 
Symbols represent statistical: ***P<0.001, **-P<0.01, *-P<0.05 
 
TREATMENT ACETYLCHOLINE  (µmol/mg) DOPAMINE (pg/ml) 
Group I (vehicle 
group) 
 
2.848 ± 0.42 
 
26.34 ± 2.20 
Group II (Negative 
control group) 
 
5.197 ± 0.28a** 
 
13.04 ± 2.24a*** 
Group III (Standard 
group) 
 
3.907 ± 0.58 
 
20.36 ± 1.89b*** 
Group IV (treatment 
group) 
 
3.052 ± 0.48b* 
 
30.10 ± 1.19b** 
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Graph No.: 20 Effects of 1, 2, 4-Triazin Derivative of diclofenac on Brain Ach 
Levels in Rat Brain 
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Graph No.:  21 Effect of 1, 2, 4-Triazin Derivative of diclofenac on Dopamine 
Assay in Chlorpromazine Induced Parkinson’s Rat  
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NSAIDs are the most common medication used in the neuro inflammatory 
disorders. Among that diclofenac is one of the prominent drugs which used in 
Parkinson’s. Diclofenac elicit appreciable GI irritation, bleeding and ulceration 
produced. Synthetic approaches based upon chemical modification of Diclofenac 
have been taken with the aim of improving safety profile and in turn therapeutic 
window. Carboxylic group is a major reason for the GI toxicity of Diclofenac, so 
Structural replacement of carboxyl group may reduce the GI toxicity. 1, 2, 4-
Triazine derivative as antagonists of Adenosine A2 receptor is expressed in the 
basal ganglia where it functionally opposes the actions of the dopamine D2 
receptor. i.e., inhibition of the A2 receptor leads to enhancement of D2 receptor 
function. Previous study reported that 1, 2, 4-Triazin derivative may possess 
appropriate Anti Parkinson’s action 13. Hence in this study carboxyl group of 
diclofenac was replaced by addition of 2- chloroacetamide to produce 1, 2, 4-
Triazin derivative of diclofenac. 
In this the intermediate and the final 1, 2, 4-Triazin derivative of diclofenac was 
confirmed by IR spectra region used to identification the functional group. The 
compounds showed the possible peak of IR (KBr), v, cm-1: CH, C=O, C-O-H, N-
H, C-N, CH2, C-Cl shows the presence of the functional groups. 
Molecular docking of 1, 2, 4-Triazin derivative of diclofenac was analysed against 
5 major targets. The Structure of 1, 2, 4- Triazin derivative of Diclofenac was 
drawn by using chem. office 2004 software and docking simulation was carried 
out against the  Parkinson’s enzyme targets like 1) Dopamine receptor D3 protein 
(3PBL),2) Dopa decarboxylase-DDC (1JS3), 3) Adenosine A2 receptor-AA2AR 
(3EML), 4) P38 map kinase (2ZAZ), 5) Monoamino oxidase-B-MAO-B (2V5Z) 
enzymes target with the help of Autodock k4 program. In this study, MAO-B , 
MAPK shows high binding site involved in this target and D3 protein, DDC, 
AA2AR, 1JS3, 3PBL shows slightly low binding site when compare to the MAO-B, 
MAPK PD which increased the binding abilities of molecular docking scores of 
designed ligand.        
  
The 1, 2, 4-Triazin derivative compound not produced any toxic symptoms or 
mortality up to the dose level of 300mg/kg orally in mice and hence, the drugs 
were considered safe for further pharmacological screening. Up to 14 days 
Additional observations will be necessary if the animals continue to display signs 
of toxicity. Observations should include changes in skin; fur, eyes and mucous 
membranes, and also cardio vascular system, central nervous systems, 
autonomic nervous and gastro intestinal tract in the animals, during the period 
test compound do not produce any major toxicity. Hence, the 1, 2, 4-Triazin 
derivative synthesized drug was selected as 1/10 of the dose that was used in the 
further pharmacological screening. Selected dose for in vivo study was 30 mg/kg. 
Induction of Parkinson’s disease in the rat was carried out by administration of 
chlorpromazine 3mg/kg, (dissolved with 1% gum acacia in distilled water 
suspension) by intra peritoneal route. Chlorpromazine drug was centrally acting 
with high affinity for dopamine D2 receptors antagonists 90. 
In PD condition reduction in the body weight during the study period development 
may be due to hypothalamic regulation, energy expenditure, or dopaminergic 
signaling mechanism 91. In treatment with 1, 2, 4-Triazine derivative group shows 
significantly increase in body weight as compare to Diclofenac group and 
chlorpromazine group. 
In this study PD condition caused decreased in feed intake and BMI variation 
which may reflect a dysregulation of dopaminergic control of eating behavior 
rather than modification of energy metabolism 92. The standard groups shows 
significantly increased, feed intake when compared to chlorpromazine group and 
the 1, 2, 4-Triazin treatment group are showed significantly increased feed intake 
when compared to standard group. 
Actophotometer was used to evaluate the effect of locomotors activity 
improvement properties of rat. Chlorpromazine induced group were exhibited 
CNS depressant effect due to impaired cholinergic transmission, oxidative / 
nitrergic stress, neuroinflammation, and dyslipidemia 93. In this study diclofenac 
treated group were showed no significant impact on locomotion when compared 
to the PD control. The 1, 2, 4-Triazin derivative of diclofenac treated group shows 
  
significantly improved spontaneous locomotor activity hence indicating its CNS 
stimulant activity in Parkinson’s rats when compared to PD control group. 
Muscle coordination activity of chlorpromazine induced rat was significantly 
decreased because in the Sensory fibers detect lengthening of the muscles and 
cause motor neurons in the spinal cord to contract the same muscles 94. In this 
study the treatment group diclofenac and 1, 2, 4-Triazin derivative of diclofenac 
showed significantly increased in muscle coordination when compared to the PD 
control.  
In this study, MWM test on the manifested itself due to immersion stress, fatigue 
and sensory-motor deficits showed in chlorpromazine Group shows significantly 
decreased 95. Cognitive function was significantly increased in both the treatment 
groups when compared to chlorpromazine group. In comparison between the 
treatment groups 1, 2, 4 Triazin group shows more increased in cognitive function 
when compare to Diclofenac Group. 
In PD condition, Catalepsy has as inability to correct an imposed abnormal 
posture while maintaining the righting reflex due to its non-selective action, it also 
produces blockade of post-synaptic D2 receptors in the nigrostriatal pathway 
leading to the development of extra pyramidal side effects. In 1, 2, 4-Triazin 
derivative treatment Group shows significantly increased in posture correction 
when compared to Diclofenac group. 
In this study, serum SGPT, SGOT, ALP, Total bilirubin, was raised in Parkinson’s 
disease rat due to liver cells damage 96. In the Diclofenac treatment and 1, 2, 4-
Triazin treatment group shows significantly low level of liver enzymes in serum. It 
reveals that the non toxic nature of diclofenac and synthesized compound on the 
liver when compared to the chlorpromazine treated Group.  
In PD condition Creatinine and urea was increased due to impaired renal 
functions evidence by an increase in serum urea and creatinine concentration 97. 
Treatment group shows significant decrease in serum creatinine and urea as 
compare to the PD control. It reveals that non toxic nature of diclofenac and 
synthesized compound on kidney when compared to the chlorpromazine treated 
Group.  
  
Brain Superoxide dismutase (known as SOD) is an enzyme which acts as a 
catalyst in the process of dismutation of superoxide into nonreactive oxygen 
species and hydrogen peroxide. It is therefore a critical antioxidant defense which 
is present in nearly all cells which are exposed to oxygen. Superoxide dismutase 
helps in neutralizing the toxic effects of free radicals 98. In this study, Diclofenac 
group showed significantly increases in SOD level when compared to 
chlorpromazine group. The 1, 2, 4-Triazin derivative treatment group shows brain 
protects against oxidation stress by significantly increases in SOD level when 
compared to chlorpromazine group.  
In this study, chlorpromazine group shows GSH depletion and reduced 
glutathione in the substantia nigra in Parkinson’s disease could be the result of 
neuronal loss. As a matter of fact, the positive correlation has been found to exist 
between the extent of neuronal loss and depletion of glutathione. A decrease in 
the availability of reduced glutathione would impair the capacity of neurons to 
detoxify hydrogen peroxide and increase the risk of free radical formation and 
lipid peroxidation 99. The treatment group shows significantly increases in GSH 
level when compared to PD control group.  
In PD condition significantly increase due to nitric oxide has been involved in the 
cytotoxicities by activation of macrophages or excess stimulation of neurons by 
glutamate 100. Diclofenac group shows significantly decrease in nitrite level when 
compared to chlorpromazine group. Treatment group shows significantly 
decrease in nitrite level when compared to PD control group 
In Chlorpromazine group shows significantly decrease in brain protein level when 
compared to control group. Treatment group shows significantly increase in 
protein level when compared to chlorpromazine alone treated group.  
Lipid peroxidation, a sensitive marker of oxidative stress, was estimated by 
measuring the levels of TBA. It is the process of oxidative degradation of 
polyunsaturated fatty acids and its occurrence in biological membranes causes 
impaired membrane function, impaired structural integrity, decreased fluidity, and 
inactivation of number of membrane bound enzymes 101. In this study, Treatment 
group shows significantly decrease in lipid peroxidation level when compared to 
chlorpromazine group.  
  
Chlorpromazine group shows significantly decrease due to catalase enzyme 
accumulation of precursor to free radical biosynthesis 102. In this study, treatment 
group shows significantly increase in catalase level when compared to control 
group. And then Diclofenac group and chlorpromazine group shows significant 
decreases in TBA when compared to Diclofenac group. 
Chlorpromazine group shows significantly increase in brain glutamate level due to 
increased density of dopamine receptor and decreased levels of dopamine is 
observed in chlorpromazine treatment 103. Treatment group shows decreased 
density of dopamine receptor by significantly decreases the glutamate level when 
compared to Chlorpromazine group. 
In this study, brain acetylcholine increase significantly in chlorpromazine alone 
treated group when compared to control group. 1, 2, 4-Triazin derivative shows 
significantly decreased in acetylcholine level when compare to chlorpromazine 
group. Diclofenac group showed no significant difference when compared to 
control group 104. 
The dopamine level in chlorpromazine induced rats was reduced significantly 
when compared to control group. Treatment groups have high dopamine level 
indicate recovering neurodegeneration.  
In ulcerogenecity Chlorpromazine Group shows mild ulceration when compared 
to control group. Diclofenac produce more ulceration when compared to control. 
In 1, 2, 4-Triazin derivative treated group shows very less incident of ulceration 
when compare to diclofenac and chlorpromazine treated group 105. 
Histopathology of mid brain portion of brain section of parkinson’s rat showed 
hyperchromatic nuclei with eosinophilic vacuolated cytoplasm in edematous. In 
treatment group shows hyperchromatic nuclei and mild vacuolization suggestive 
of mild degenerative changes in treated animals 106. It conforms the diclofenac 
and 1, 2, 4-Triazin derivative treatment shows greater effect on neuronal 
inflammation.   
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Parkinsonism disease (PD) is neurodegenerative disorder, is characterized 
by progressive loss of dopamine (DA) neurons in the substantial nigra pars 
compacta (SNpc), leading to striatal DA depletion. This degeneration of 
Dopaminergic nigrostriatal system is largely responsible for the classical motor 
signs, including resting tremor, muscle rigidity, and bradykinesia. Molecular 
docking study of 1, 2, 4 -Triazin Analogue of diclofenac shows greater interaction 
against MAO-B and MAPK as compared to the D3 protein, DDC and AA2AR 
targets.   
In this study the carboxylic group of diclofenac was replaced with 2-
Chloroacetamide to produce the 1, 2, 4 - Triazin derivative of diclofenac as 
potential target for PD. The functional groups are confirmed by IR spectra 
functional group peaks.   
PD was induced in this study by administration of chlorpromazine due to its 
D2 dopamine receptor blockade action. It confirms the decreased locomotors 
function, muscle coordination, cognitive function and deflects of dopamine, also 
increased in muscle rigidity, oxidative stress and cholinergic activity in the 
chlorpromazine alone administered group. 
Diclofenac and 1, 2, 4 - Triazin derivative of diclofenac treatments 
significantly revert all this complication of PD. But the ulcerogenisity was 
significantly higher in diclofenac treated group on continuous 14 day treatment it 
might be due to its carboxyl group and the treatment of 1, 2, 4 - Triazin derivative 
of diclofenac posses more potent anti-parkinson activity with negligible ulcer as 
compared to the diclofenac treatment. It might be due to the replacement of 
carboxyl group of diclofenac with 2-chloroacetamide and also the potent action of 
1, 2, 4 triazine against PD.           
In conclusion replacement of carboxyl group of diclofenac with 2-
chloroacetamide to produce a 1, 2, 4 triazine analogue as a potent ligand for 
parkinson’s disease with minimal GI toxicity. Further clinical data are required to 
  
explore this synthesised Analogue of Diclofenac as Potential Ligand for improving 
the status of PD patients. 
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